Entries |
Document | Title | Date |
20080200660 | Method for the hydrophobisation of DNA molecules - The present invention relates to a method for the hydrophobisation of DNA molecules comprising mixing an aqueous solution of the DNA molecule with a solution of a cationic lipid or a surfactant in an organic solvent under agitation for a period in the range of 30 to 60 minutes to obtain the hydrophobic DNA in organic phase. | 08-21-2008 |
20080200661 | COMPOSITION FOR IN VIVO DELIVERY - The present invention relates to the delivery of desired compounds (e.g., nucleic acids) into cells using releasable delivery systems which include complexing nucleic acids and delivery ligands. | 08-21-2008 |
20080207883 | Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes - This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same. | 08-28-2008 |
20080207884 | siRNA targeting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to ATIC. | 08-28-2008 |
20080207885 | Method for site-specific labeling of RNA using a deoxyribozyme - The present invention is a method for site-specific internal RNA modification. In accordance with the present method, a deoxyribozyme (DNA enzyme) is used as a catalyst to attach a tagging RNA to a pre-determined internal position of a target RNA molecule, wherein the tagging RNA is coupled to a label prior to or after attachment to the target RNA molecule thereby labeling the target RNA. | 08-28-2008 |
20080221315 | NUCLEIC ACID-BASED TRANSLATION SYSTEM AND METHOD FOR DECODING NUCLEIC ACID ENCRYPTED MESSAGE - A nucleic acid-based translation system where the components of a nucleic acid multicrossover molecule serve as message, translation device and part of the translated product. One continuous strand of a nucleic acid multicrossover molecule acts as a message, which nucleic acid crossover strands, functioning together as a translation device, translate into nucleic acid product strands. Organic molecules appended to the backbone of the nucleic acid product strands can also be polymerized to form a polymer sequence of appended organic molecules. | 09-11-2008 |
20080227965 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers - The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences. | 09-18-2008 |
20080249291 | Oligonucleotides Derived From Mycobacterium for Stimulating Immune Function, Treating Immune-Related Diseases, Atopic Dermatitis and/or Protecting Normal Immune Cell - Disclosed are oligonucleotides for manipulating an immune reaction. The oligonucleotides of the present invention may be useful to stimulate the immune function, to treat the immune-related diseases and the atopic dermatitis, or to protect the normal immune cells. | 10-09-2008 |
20080262210 | Immunostimulating Agents - Disclosed is a new type of immunostimulating agent including an immunostimulating oligonucleotide complexed with a carrier which is safe and has a high transfection effect. The carrier complexed with the immunostimulating oligonucleotide to form the immunostimulating agent is a polysaccharide having β-1,3-bonds (preferably β-1,3-glucan such as schizophyllan). A preferred example of the immunostimulating oligonucleotide is one containing an unmethylated CpG motif. The polysaccharide for use is preferably modified with nucleic acid-binding functional group and/or cell membrane-affinitive functional group. | 10-23-2008 |
20080300394 | DEFECTIVE SINDBIS VIRAL VECTORS - Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for producing the vectors, methods for treating mammals suffering from tumors and pharmaceutical formulations for use in the treatment methods. | 12-04-2008 |
20090012280 | OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING NIDOVIRUS INFECTIONS - A method and oligonucleotide compound for inhibiting replication of a nidovirus in virus-infected animal cells are disclosed. The compound (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the infected cells, (iii) contains between 8-25 nucleotide bases, and (iv) has a sequence capable of disrupting base pairing between the transcriptional regulatory sequences in the 5′ leader region of the positive-strand viral genome and negative-strand 3′ subgenomic region. In practicing the method, infected cells are exposed to the compound in an amount effective to inhibit viral replication. | 01-08-2009 |
20090012281 | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS - The present invention provides 6-modified bicyclic nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 6-position. These bicyclicnucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance. | 01-08-2009 |
20090018319 | DNA sequence in plant Caragana jubata with freeze tolerance - Abstract An isolated DNA sequence set forth in SEQ ID NO: 32, which is differentially expressed in apical buds of plant | 01-15-2009 |
20090023905 | Transgenic animal model of bone mass modulation - The present invention relates to methods and materials used to express the HBM protein in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis. | 01-22-2009 |
20090023906 | DRIED OLIGONUCLEOTIDE COMPOSITION AND METHOD OF PRODUCING THE SAME - The present invention relates to a dried oligonucleotide composition and a method for producing the same. More specifically, it relates to a dried oligonucleotide composition produced by the steps comprising adding a substance for preventing the oligonucleotide from being separated and lost, which is adhesive to a storage container containing the oligonucleotide composition, in order to prevent the oligonucleotide from being separated and lost during manufacturing and distributing the dried oligonucleotide composition, optionally adding a non-reactive dye substance, and drying the resulting solution. The dried oligonucleotide composition of the present invention can be prevented from being separated and lost during manufacturing step, or transporting step after packaging, and the presence or absence of the oligonucleotide in the storage container can be easily confirmed with naked eyes. Accordingly, unnecessary labor waste and time waste caused by the separation of the oligonucleotide upon experiment can be overcome. | 01-22-2009 |
20090030189 | mTOR GLS and ELS, their small molecule mimetics and competitive inhibitors - The present invention relates generally to molecular mechanisms of mTOR-related human diseases. More specifically, the invention relates to two novel related polypeptides, the ER-localization sequence (ELS) and Golgi-localization sequence (GLS) along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins. | 01-29-2009 |
20090036660 | Methods and compositions for generating mixtures of nucleic acid molecules - In some embodiments, the present disclosure provides methods of making a mixture of nucleic acid molecules, the methods comprising the steps of: synthesizing on a substrate a population of nucleic acid molecules wherein each synthesized nucleic acid molecule comprises a substrate-attached proximal nucleic acid molecule, a distal nucleic acid molecule, and a cleavable linker linking the proximal nucleic acid molecule to the distal nucleic acid molecule, and harvesting distal nucleic acid molecules from the substrate by cleaving the cleavable linker under conditions that do not release the proximal nucleic acid molecule. Related compositions and kits are also provided. | 02-05-2009 |
20090043082 | MICRORNA AND METHODS FOR INHIBITING SAME - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules. | 02-12-2009 |
20090043083 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery. | 02-12-2009 |
20090048434 | Compositions and methods relating to orthogonal ribosome mRNA pairs - Orthogonal ribosome orthogonal mRNA pairs are provided, as are methods for their selection involving a novel positive-negative selection approach, and methods for their use. Also provided are cellular logic circuits involving orthogonal ribosomes. | 02-19-2009 |
20090062520 | Method of producing DNA structure and DNA structure - The present invention provides a method of producing a DNA structure in which multiple quadruplex DNAs are linked, which includes (a) a step of mixing multiple DNA molecules having an antiparallel quadruplex structural part, and at least two single stranded sticky ends extended from the end of the quadruplex structural part, wherein the single stranded sticky end of the each DNA molecule has a base sequence that can form a duplex through interaction with the single stranded sticky end of other DNA molecule. | 03-05-2009 |
20090062521 | AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID - To provide an excellent amidite for synthesizing modified nucleic acid, which enables a protective group therein to be removed under a moderate condition, thereby stably producing a hydroxyl group-containing modified nucleic acid, and a method for synthesizing modified nucleic acid using the amidite. Specifically, an amidite for synthesizing modified nucleic acid, expressed by General Formula (I): | 03-05-2009 |
20090082554 | Thiocarbonate linkers for polynucleotides - In various embodiments of the invention, novel compositions having a polynucleotide bound to a substrate via a cleavable linker are provided, and methods of cleaving a polynucleotide from a substrate are provided. | 03-26-2009 |
20090088560 | Process for Nucleic Acid Purification - This invention provides a method of isolating and purifying nucleic acid using a binding buffer comprising a sodium- or potassium-ion-containing solution with the final concentrations of either sodium- or potassium-ion concentration of at least about 500 mM, preferably greater than about 1 M to saturate, and the pH of such solution of being adjusted in the range of about 2.0 to 5.0, for reversible binding of the nucleic acid to a silicon-containing matrix. The invention further provides a method of increasing reversible binding of the nucleic acid to a silicon-containing matrix using the binding buffer of the invention in addition to 20% to 50% (v/v) of a water-soluble organic solvent, e.g., ethanol. Nucleic acid obtained thereof that is free of chaotropes and other toxic chemicals, and nucleic acid purification kits comprising the binding buffer of the invention are also provided. | 04-02-2009 |
20090093621 | Novel peptides comprising repetitive units of amino acids and DNA sequences encoding the same - Novel polypeptides comprising repetitive units of amino acids, as well as synthetic genes encoding the subject polypeptides are provided. The subject polypeptides are characterized by comprising repetitive units of amino acids, where the repetitive units are present in naturally occurring proteins, particularly naturally occurring structural proteins. The subject polypeptides find use in a variety of applications, such as structural components of prosthetic devices, synthetic fibers, and the like. | 04-09-2009 |
20090093622 | BASB029 polynucleotide(s) and polypeptides from Neisseria meningitidis - The invention provides BASB029 polypeptides and polynucleotides encoding BASB029 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. | 04-09-2009 |
20090111976 | Identification of the gene and mutation responsible for progressive rod-cone degeneration in dog and a method for testing same - Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1. | 04-30-2009 |
20090118483 | Light-driven energy generation using proteorhodopsin - A light-driven energy generation system using proteorhodopsin is provided. The system includes a light source, a host with a correctly folded, integrated proteorhodopsin protein, a source of retinal, and a mediator. The source of retinal binds covalently to the integrated proteorhodopsin protein, thereby creating a light absorbing pigment. Illumination of the light absorbing pigment with the light source results in conversion of light energy to biochemical energy. This biochemical energy is harnessed by the mediator to produce light-driven energy, such as mechanical, chemical or electrical energy. | 05-07-2009 |
20090118484 | FORMATION OF NOVEL NUCLEIC ACID COMPLEXES AND DETECTION THEREOF - This invention relates to a process and system to amplify and detect recombinational non-reciprocal cross-over reactions between homologous nucleic acid molecules without the assistance from a protein factor. The result of a chain reaction of non-reciprocal cross-overs is stoichiometrical formation of nucleic acid conglomerate complex that binds significantly more ethidium bromide or other fluorophores than a canonical B-form double helical nucleic acid does, emitting much stronger fluorescence. Such nucleic acid conglomerate complex can be easily detected by conventional methods, therefore can be used to detect any target molecule of interest. | 05-07-2009 |
20090118485 | OLIGONUCLEOTIDES AND ANALOGS LABELED WITH ENERGY TRANSFER DYES - Novel linkers for linking a donor dye to an acceptor dye in an energy transfer fluorescent dye are provided. These linkers faciliate the efficient transfer of energy between a donor and acceptor dye in an energy transfer dye. One of these linkers for linking a donor dye to an acceptor dye in an energy transfer fluorescent dye has the general structure R | 05-07-2009 |
20090124793 | Corticotropin releasing factor 2 receptor agonists - Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy. | 05-14-2009 |
20090131644 | HERPESVIRUS RIBOZYMES AND VECTORS - Hammerhead ribozymes that target components critical to HSV replication (ICP4, U | 05-21-2009 |
20090149640 | NUCLEIC ACID LADDERS - The present invention provides nucleic acid molecules which may be used as standards for estimating the size (in base pairs) and mass of linear, double-stranded or single-stranded nucleic acid molecules separated by size. The nucleic acid molecules of the invention may be DNA molecules, RNA molecules or DNA/RNA hybrid molecules, and may be double-stranded or single-stranded. The invention also provides methods for producing nucleic acid sizing ladders from these nucleic acid molecules, ladders produced by such methods, and methods for estimating the size and mass of nucleic acid molecules by comparison to these nucleic acid sizing ladders. | 06-11-2009 |
20090156792 | BIS-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS - The present disclosure describes bis-modified bicyclic nucleosides and oligomeric compounds that can be prepared comprising at least one of these bis-modified bicyclic nucleosides. More particularly, the bis-modified bicyclic nucleosides have at least one substituent group at the 5′-methylene and on the bridge methylene and can be chiral. These bis-modified bicyclic nucleosides are expected to be useful for enhancing one or more property of oligomeric compounds including for example enhancing nuclease resistance. | 06-18-2009 |
20090156793 | Circular Chromosomes - Circular chromosomes with centromere DNA comprise recombination sites flanking a region with bacterial replication DNA and a recombinase transcription unit. Circular chromosomes without bacterial replication DNA are formed by removing bacterial replication DNA from a circular chromosome by action of a recombinase that excises DNA between said recombination sites. | 06-18-2009 |
20090171075 | Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo - Preparations of novel molecular transporter compositions and their use for transporting bioactive substances into cells in living animals are disclosed. To afford in vivo delivery, the composition is covalently linked to the bioactive substance and the resultant composite structure is introduced into the subject. The transporter composition includes multiple guanidine moieties on a dendrimeric scaffold having a triazine core. | 07-02-2009 |
20090192303 | NUCLEIC ACID EXTRACTION METHOD - The present invention relates to a method for isolating nucleic acids from a nucleic acid containing sample, and a kit for carrying out said method. More specifically, it relates to a novel method for extracting nucleic acids from a nucleic acid containing sample, using an anion exchange solid support, and allowing this solid phase with the nucleic acid bound thereto to react with a compound which is also capable of binding to said anion exchange solid support and which optionally provides additional charges at the surface of the anion exchange solid material, thereby preferably changing the surface charge density of the solid support and then releasing the nucleic acid from the solid support, eliminating the need for high salt and/or high pH elution buffers. | 07-30-2009 |
20090198047 | 2'-Modified Oligonucleotides - Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2′-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided. | 08-06-2009 |
20090203890 | HEPATITIS C ANTIVIRALS - The present invention relates to deoxyribozymes targeting and cleaving HCV RNA. More particularly, the present invention relates to deoxyribozymes and composition used for the inhibition of HCV replication and HCV-related diseases. | 08-13-2009 |
20090209748 | OLIGONUCLEOTIDES WITH ALTERNATING SEGMENTS OF LOCKED AND NON-LOCKED NUCLEOTIDES - The present invention is directed to novel oligonucleotides with improved antisense properties. The novel oligonucleotides comprise at least one Locked Nucleic Acid (LNA) selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides. The present invention also provides a new class of pharmaceuticals which comprise antisense oligonucleotides and are useful in antisense therapy. | 08-20-2009 |
20090216003 | STABLE AND SELECTIVE FORMATION OF HOOGSTEEN-TYPE TRIPLEXES AND DUPLEXES USING TWISTED INTERCALATING NUCLEIC ACIDS (TINA) AND PROCESS FOR THE PREPARATION OF TINA - The present invention describes a flexible basestacking monomer that can be incorporated into an oligonucleotide or oligonucleotide analogue, as well as triplex forming oligonucleotides comprising the flexible basestacking monomer. Triplex forming oligonucleotides of the invention are capable of binding sequence specifically to doublestranded target nucleic acids and are therefore of interest for modulation of the activity of target nucleic acids and also detection of target nucleic acids. | 08-27-2009 |
20090221807 | 2' Deoxy-2'-Alkylnucleotide Containing Nucleic Acid - 2′-deoxy-2′-alkylnucleotides useful for stabilizing enzymatic nucleic acid molecules and antisense molecules. | 09-03-2009 |
20090253901 | Nanoencapsulation and Release of Nucleic Acids - A method for Encapsulation of nucleic acids such as DNA, RNA any other types of nucleotides via entrapping or co-precipitation in CaCO3 porous microparticles followed by polymeric shell deposition or polymer nanoparticles composite shell deposition. This method can be used for controlled delivery and release of nucleic acids. | 10-08-2009 |
20090259031 | CHIMERIC AND HUMANIZED ANTIBODIES TO alpha5beta1 INTEGRIN THAT MODULATE ANGIOGENESIS - The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same. | 10-15-2009 |
20090270601 | Differential detection of single nucleotide polymorphisms - This application claims processes and compositions that enable discovery of single nucleotide polymorphisms (SNPs) and other sequence variation that follows two essentially identical sequences, one a reference, the other a target, as well as SNPs discovered using these processes and compositions. The inventive process comprises preparation of four sets of primers, “T-extendable”, “A-extendable”, “C-extendable”, and “G-extendable”. These primers, when templated on a reference genome, add (respectively) T, A, C, and G to their 3′-ends. The invention also comprises a step where these primer sets are separately bound to complementary sequences on target DNA and, once bound, prime extension reactions using target DNA as the template. If the target DNA directs incorporation of the same nucleotide as the reference DNA, then the T-, A-, C-, and G-extendable primers are extended (respectively) by T, A, C, and G. The architecture of the process distinguishes products from these extensions from products derived if not T, not A, not C and not G (“3N” or “3”, to indicate the other three nucleotides) are not added. Thus, this process discovers differences between the target and reference DNA in the site queried by the primer extension reaction. The distinction makes the two kinds of products either separable or differentially extendable. This distinction is used to disregard products that added T, A, C, and G and to identify the sequence(s) of primers that added not-T, not-A, not-C, and not-G. Further and optionally, information from these sequences identifies loci of the SNPs in an in silico genome. | 10-29-2009 |
20090286969 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs - Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided. | 11-19-2009 |
20090299043 | Template-Synthesized DNA Nanotubes - A method of forming DNA nanotubes composed entirely or predominantly from DNA that, The methods of the present invention form single layer or multilayer template-synthesized nanotubes where the bulk of the tube is composed of DNA, and the layers are held together by hybridization of complementary DNA strands. The DNA molecules making up these tubes may be varied as desired, and the DNA is capable of being released from the tube. | 12-03-2009 |
20090312532 | Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secodary rna structure - The invention provides a method for generating an oligonucleotide with which an exon may be skipped in a pre-mRNA and thus excluded from a produced mRNA thereof. Further provided are methods for altering the binding of an SR protein and/or methods for altering the secondary structure of an mRNA to interfere with splicing processes and uses of the oligonucleotides and methods in the treatment of disease. Further provided are pharmaceutical compositions and methods and means for inducing skipping of several exons in a pre-mRNA. | 12-17-2009 |
20090318676 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE - One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3′-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a non-phosphate linkage occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands. In certain embodiments, a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a ligand is bound to the oligonucleotide strand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety. | 12-24-2009 |
20090326208 | Methods and compositions for generating recombinant nucleic acid molecules - A method of generating a double stranded (ds) recombinant nucleic acid molecule covalently linked in both strands by contacting two or more ds nucleotide sequences with a topoisomerase under conditions such that both termini of at least one end of a first ds nucleotide sequence are covalently linked by the topoisomerase to both termini of at least one end of a second ds nucleotide sequence is provided. Also provided is a method for generating a ds recombinant nucleic acid molecule covalently linked in one strand, by contacting two or more ds nucleotide sequences with a type IA topoisomerase under conditions such that one strand, but not both strands, of one or both ends of a first ds nucleotide sequence are covalently linked by the topoisomerase. Compositions for performing such methods, and compositions generated from such methods also are provided, as are kits containing components useful for conveniently practicing the methods. | 12-31-2009 |
20090326209 | Method for isolating and modifying DNA from blood and body fluids - This invention is related a method for rapidly isolating and modifying DNA from plasma/serum and body fluids. This invention provides a procedure and composition to obtain a high yield of modified DNA for methylation-specific PCR assay by coupling DNA isolation and modification courses. | 12-31-2009 |
20100016566 | Method of synthesizing cdna and method of synthesizing rna chains, and nucleotide-immobilized carrier - A method of synthesizing a cDNA chain using an insoluble carrier having on the surface thereof a polymer substance containing a first unit having a group derived from a phosphoric ester composing the hydrophilic portion of phospholipid, and a second unit having a group derived from carboxylic acid having an electron-attractive substituent bound to a carbonyl group, which includes immobilizing a polynucleotide for DNA elongation; bringing a solution containing an RNA fragment, nucleotide monomers, and a reverse transcriptase or an enzyme having polymerase activity into contact with the surface of the insoluble carrier; and allowing the polynucleotide for DNA elongation immobilized on the surface of the carrier to elongate using the RNA fragment contained in the solution as a template, to thereby form a single-strand cDNA. | 01-21-2010 |
20100016567 | PROCESS FOR PRODUCING DI(PYRIMIDINE NUCLEOSIDE 5'-)POLYPHOSPHATE - A di(pyrimidine nucleoside 5′-)polyphosphate is synthesized by converting a pyrimidine nucleoside 5′-triphosphate into a pyrimidine nucleoside 5′-cyclic triphosphate by use of a condensing agent, and subsequently reacting the pyrimidine nucleoside 5′-cyclic triphosphate with a pyrimidine nucleotide in the presence of a salt of a metal selected from among magnesium, manganese, and iron. | 01-21-2010 |
20100016568 | CELLOMICS SYSTEM - In labeling a cell, and separating and collecting the cell according to a degree of the labeling using a cell separator, effects on the cell is minimized and the use of the collected cell is facilitated, thereby, when labeling a cell, the cell is labeled in the state where interaction of each cell is retained. In the labeling, a specific labeling material present on a surface of a target cell is taken in the cell via a transporter, and the cell is dispersed one by one to separate the same with a cell separator. Immediately after the separation, the cell is put in a solution not containing the specific labeling substance to remove the specific labeling substance taken in the cell. This series of steps is continuously conducted with a cell separation chip. | 01-21-2010 |
20100016569 | CELLOMICS SYSTEM - In labeling a cell, and separating and collecting the cell according to a degree of the labeling using a cell separator, effects on the cell is minimized and the use of the collected cell is facilitated, thereby, when labeling a cell, the cell is labeled in the state where interaction of each cell is retained. In the labeling, a specific labeling material present on a surface of a target cell is taken in the cell via a transporter, and the cell is dispersed one by one to separate the same with a cell separator. Immediately after the separation, the cell is put in a solution not containing the specific labeling substance to remove the specific labeling substance taken in the cell. This series of steps is continuously conducted with a cell separation chip. | 01-21-2010 |
20100022761 | PHOTOCLEAVABLE LINKER METHODS AND COMPOSITIONS - Bifunctional linkers are provided that comprise a photocleavable moiety flanked by two different amine reactive moieties. In some embodiments the photocleavable moiety is a dimethoxynitrobenzyl moiety. In other embodiments the photocleavable moiety is 8-bromo-7-hydroxyquinoline. In other embodiments the photocleavable moiety is nitrodibenzofuran. In other embodiments the photocleavable moiety is 6-bromo-7-hydroxycoumarin-4-ylmethyl. The linkers find use in synthetic methods, including the generation of photocleavable oligonucleotides, e.g. caged morpholinos. | 01-28-2010 |
20100029920 | METHOD FOR ASSESSING THE EFFECT OF A DRUG ON LONG TERM MEMORY FORMATION - Methods of assessing the effect of a drug on long term memory and for screening a pharmaceutical agent for its ability to modulate long term memory are disclosed. | 02-04-2010 |
20100029921 | Trioxyethylene Gold Nanoclusters Functionalized with a Single DNA - A method of making a nanoclusters functionalized with a single DNA strand comprising the steps of providing nanoclusters, combining said nanoclusters with thiolated DNA, incubating said nanoclusters and thiolated DNA mixture, combining said mixture with a solution comprising ethanol and dichloromethane; separating said mixture into an aqueous phase and an organic phase, mixing said aqueous phase with a solution comprising dicholormethane and NaCl, and separating the mixture into an aqueous phase and an organic phase; wherein said organic phase comprises said nanoclusters functionalized with a single DNA strand. Further, provided is a nanocluster functionalized with a single DNA strand comprising a nanocluster, said nanocluster being functionalized with a single DNA strand, said DNA strand having a length of about 10 to about 50 bases. | 02-04-2010 |
20100036104 | DETECTION OF NUCLEIC ACIDS BY TARGET-SPECIFIC HYBRID CAPTURE METHOD - Target-specific hybrid capture (TSHC) provides a nucleic acid detection method that is not only rapid and sensitive, but is also highly specific and capable of discriminating highly homologous nucleic acid target sequences. The method produces DNA:RNA hybrids which can be detected by a variety of methods. | 02-11-2010 |
20100036105 | RNA complexes, methods of their production - The invention includes RNA complexes comprising at least three monomeric units of an RNA molecule, each monomeric unit comprising an RNA polymer having first and second helical domains that have respective first and second binding sites, wherein the first binding sites are adapted to binding to one another and are not adapted to bind to the second binding sites, and the second binding sites are adapted to binding to one another and are not adapted to bind to the first binding sites; such that the at least three monomeric units are adapted to self-assemble by forming pairs of cognate interactions and so as to form the RNA complex in a circular closed complex. The invention also includes derivatives of these complexes including aptamers, and analytical methods and devices using same. | 02-11-2010 |
20100048883 | METHOD FOR PURIFYING RNA ON A PREPARATIVE SCALE BY MEANS OF HPLC - The application describes a method for the preparative purification of RNA, which method is distinguished in that the RNA is purified by means of HPLC using a porous reversed phase as the stationary phase. The use of the porous reversed phase in this HPLC method is also described. | 02-25-2010 |
20100056768 | HYDROXYMETHYL SUBSTITUTED RNA OLIGONUCLEOTIDES AND RNA COMPLEXES - The present invention is directed to RNA oligonucleotides or complexes of RNA oligonucleotides, denoted herein together as RNA complexes, containing at least one, but optionally more that one, hydroxymethyl substituted nucleotide monomer(s). By a hydroxymethyl substituted nucleotide monomer is understood a nucleotide monomer containing a hydroxymethyl group (that may be unsubstituted, O-substituted for example with a conjugating group, or converted into an optionally substituted or conjugated aminomethyl group). This hydroxymethyl group is not partaking in formation of an internucleotide linkage and is not the hydroxymethyl group (containing the 5′-hydroxy group) of a natural RNA monomer. The RNA complexes of the invention may be useful for therapeutic applications, diagnostic applications or research applications. The complexes include short interfering RNA complexes (siRNA duplexes) comprising an antisense strand and a continued or a discontinued passenger strand (“sense strand”) capable of regulating gene expression. At least one of these strands, possible more than one of these strands, are modified with one or more hydroxymethyl substituted nucleotide monomer(s) of this invention, that can be positioned at the 3′-end, at the 5′-end or internally. The RNA complexes of the invention can also be single stranded RNA oligonucleotides (“RNA strands”) that are modified with at least one, but optionally more that one, hydroxymethyl substituted nucleotide monomer(s). Such single stranded RNA strands are to be considered included whenever the term RNA complexes is used in this patent application. The complexes of the invention display enhanced stability towards nucleolytic degradation relative to the corresponding complexes comprised entirely from natural RNA monomers. | 03-04-2010 |
20100063263 | Magnetic particles with a closed ultrathin silica layer, method for the production thereof and their use - The invention relates to magnetic particles coated with silica (Si02), whereby the silicate layer is closed and tight and is characterized by having an extremely small thickness on the scale of a few nanometers—hereafter also referred to as a silica nanolayer. This invention also relates to an improved method for producing these silicate-containing magnetic particles that, in comparison to the prior art, lead to a product having a closed silicate layer and thus entail a highly improved purity. In addition, the novel method prevents an uncontrolled formation of aggregates and clusters of silicates on the magnetite surface, thereby having a positive influence on the properties and biological applications cited below. The novel method also enables the depletion of nanoparticulate solid substance particles on the basis of a fractionated centrifugation. The inventive magnetic particles exhibit an optimized magnetization and suspension behavior as well as a very advantageous run-off behavior from plastic surfaces. These highly pure magnetic particles coated with silicon dioxide are preferably used for isolating nucleic acids from cell and tissue samples, whereby the separating out from a sample matrix ensues by means of magnetic fields. These particles are particularly well suited for the automatic purification of nucleic acids, mostly from biological body samples for the purpose of analyzing them with different amplification methods. | 03-11-2010 |
20100063264 | NUCLEOTIDE SEQUENCING VIA REPETITIVE SINGLE MOLECULE HYBRIDIZATION - Methods of obtaining sequence information about target oligonucleotides by repetitive single molecule hybridization are disclosed. The methods include exposing a target oligonucleotide to one or more copies of a test oligonucleotide; measuring hybridization; dehybridizing the test oligonucleotide; and repeating until the information content from the hybridization trials equals or exceeds the information content of the target oligonucleotide. | 03-11-2010 |
20100063265 | CORN EVENT 3272 AND METHODS OF DETECTION THEREOF - A novel transgenic corn event designated 3272, is disclosed. The invention relates to DNA sequences of the recombinant constructs inserted into the corn genome that resulted in the 3272 event and of genomic sequences flanking the insertion sites as well as to assays for detecting the presence of the 3272 event based on these novel sequences. The invention further relates to seeds of corn plants comprising the 3272 genotype, to corn plants comprising the genotype of 3272 and to methods for producing a corn plant by crossing a corn plant comprising the 3272 genotype with itself or another corn variety. | 03-11-2010 |
20100069620 | NOVEL COMPOSITIONS OF CHEMICALLY MODIFIED SMALL INTERFERING RNA - The present invention is directed to compositions comprising chemically modified siRNA that have high specificity by virtue of no or insignificant off-target activity of the sense strand, no or insignificant induction of IFN-like responses, high potency to offset oligonucleotide manufacturing costs, favorable manufacturing chemistry, and effective means of intracellular delivery both in vitro, during target validation and model studies, and in vivo, during animal model studies and clinical trials in humans. | 03-18-2010 |
20100069621 | POLYNUCLEOTIDES AND RELATED NANOASSEMBLIES, STRUCTURES, ARRANGEMENTS, METHODS AND SYSTEMS - A linker polynucleotide for attaching a nanomaterial to a polynucleotidic platform and related nanoassemblies, arrangements, structures, methods and systems. | 03-18-2010 |
20100081801 | Method for determining an unknown PNA sequence and uses thereof - The invention relates to a method for determining an unknown PNA sequence information of PNA molecules of a specific PNA molecule species, wherein, the PNA molecules are contacted with one or several different nucleic acid molecule species comprising nucleic acid molecules with at least one nucleotide, wherein the nucleic acid molecules at least partially comprise a nucleic acid sequence that is complementary to at least a partial sequence of the PNA molecule, wherein nucleic acid molecules having complementary sequences bind to the PNA molecules forming nucleic acid/PNA hybrids, wherein nucleic acid molecules with non-complementary sequences are separated from the nucleic acid/PNA hybrids, wherein thereafter the nucleic acid/PNA hybrids are dissociated into single stranded hybrid nucleic acid molecules and PNA molecules, wherein the single stranded hybrid nucleic acid molecules are subjected to a sequencing process providing hybrid sequence information about the single stranded hybrid nucleic acid sequence, and wherein the hybrid sequence information is optionally translated into the complementary PNA sequence information, and to a method for producing PNA molecules using such a process. | 04-01-2010 |
20100093985 | USE OF AT LEAST ONE CYTOSOLIC PHOSPHOLIPASE A2 INHIBITOR AS A MEDICINE FOR SYMPTOMATIC TREATMENT OF MUCOVISCIDOSIS - A subject of the invention is the use of at least one cytosolic phospholipase A2 (cPLA2) inhibitor in the preparation of a medicament intended for the preventive and/or curative symptomatic treatment of cystic fibrosis, particularly of the increased secretion of mucus in cystic fibrosis. | 04-15-2010 |
20100093986 | METHODS OF DIRECT GENOMIC SELECTION USING HIGH DENSITY OLIGONUCLEOTIDE MICROARRAYS - The present disclosure encompasses methods (hereinafter termed ‘Microarray-based Genomic Selection’ (MGS), capable of isolating user-defined unique genomic sequences from complex eukaryotic genomes. | 04-15-2010 |
20100099858 | Maximizing Oligonucleotide Loading on Gold Nanoparticle - Increasing the amount of DNA loaded onto gold nanoparticles is disclosed. More particularly, methods of maximizing DNA loading, using salting techniques, sonication, temperature and other such procedures are disclosed. | 04-22-2010 |
20100113758 | METHOD FOR PURIFYING BIOMOLECULES - The present invention relates to a process for the purification of biomolecules, in particular of nucleic acids, such as DNA and RNA molecules. | 05-06-2010 |
20100113759 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS - The present teachings relate to nucleobase, nucleoside and nucleotide compounds, methods of synthesis, and uses thereof. The present teachings provide compounds, such as nucleobase, nucleoside and/or nucleotide compounds including a propargyl linker, and methods for making or using such compounds. | 05-06-2010 |
20100125134 | METHOD OF SEPARATING GENOMIC DNA AND PLASMID DNA FROM EACH OTHER AND KIT THEREFOR - Provided are a method of separating genome DNA and plasmid DNA from each other from a sample using a binding buffer containing a high concentration kosmotropic salt and chaotropic salt, and a kit therefor. | 05-20-2010 |
20100137570 | HOST CELL PROTEIN KNOCK-OUT CELLS FOR PRODUCTION OF THERAPEUTIC PROTEINS - The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described. | 06-03-2010 |
20100152431 | COMPOSITIONS, PROBES AND CONJUGATES AND USES THEREOF - The present invention relates to compositions useful as probes and in other applications and methods of their use. In some embodiments, nucleotides are prepared and functionalized with dyes. In some embodiments a first molecule is functionalized with an alkynyl group, a second molecule is functionalized with an azide group, and said first and second molecules are mixed under conditions to form a conjugate with a 1,2,3-triazol group. In further embodiments, a nucleotide is functionalized with an alkynyl group, a dye is functionalized with an azide group, and mixing the nucleotide and the dye forms a conjugate capable of emitting light. | 06-17-2010 |
20100160617 | NUCLEASE-RESISTANT RNA APTAMER INHIBITING REPLICATION OF HEPATITIS C VIRUS REPLICON - Disclosed a nuclease-resistant RNA aptamer for inhibiting the replication of HCV replicon. This aptamer is capable of binding specifically to HCV NS5B and inhibiting the proliferation of the HCV replicon, and is composed of at least one sequence selected from a group consisting of SEQ ID NOS. 1 to 4, in which a fluoro group is substituted for 2′-hydroxy of both U (uracil) and C (cytosine) bases, and SEQ ID NO. 4, which is tagged with a cholesteryl group at a 5′ end and with idT at a 3′ end. The RNA aptamer is useful in the diagnosis and treatment of HCV infection. | 06-24-2010 |
20100160618 | Expanding the eukaryotic genetic code - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided. | 06-24-2010 |
20100168408 | COMPOSITIONS AND METHODS FOR LABELING OF NUCLEIC ACID MOLECULES - The present invention is generally related to compositions, kits and methods for labeling nucleic acid molecules using reverse transcriptases, preferably multi-subunit reverse transcriptases such as ASLV reverse transcriptases. Specifically, the invention relates to methods, kits and compositions for to fluorescently labeling nucleic acid molecules during nucleic acid synthesis. The labeled nucleic acid molecules produced in accordance with the invention are particularly suited as labeled probes for nucleic acid detection and diagnostics. | 07-01-2010 |
20100184966 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS - The present invention provides 5′-modified bicyclic nucleoside analogs and oligomeric compounds comprising at least one of these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 5′-carbon. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including for example enhanced nuclease resistance. | 07-22-2010 |
20100190970 | GENETIC LESION ASSOCIATED WITH CANCER - The invention comprises methods for identifying mutations within the 3′ UTRs of genes that lead to increased risk or probability of developing cancer. | 07-29-2010 |
20100197899 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A 2-ARYLPROPYL MOIETY - The present invention provides single-stranded and double-stranded oligonucleotides comprising at least one aralkyl ligand that improvise the pharmacokinetic properties of the oligonucleotide. The aralkyl ligands of the present invention include naproxen, ibuprofen, and derivatives thereof. The present invention also provides method for modulating gene expression using the modified oligonucleotide compounds and compositions comprising those modified oligonucleotides. | 08-05-2010 |
20100197900 | MODULATORS OF COAGULATION FACTORS - The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acid ligands to provide ideal modulators of coagulation. These improved nucleic acid ligands and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass. | 08-05-2010 |
20100222559 | NUCLEIC ACID MOLECULE CAPABLE OF BINDING TO RABBIT-DERIVED lgG ANTIBODY - The present invention provides a nucleic acid molecule having an ability to bind to a rabbit anti-mouse IgG antibody, which can be prepared more easily than an antibody and has a binding ability equal to or higher than that of an antibody. The nucleic acid molecule according to the present invention may have the sequences set forth in SEQ ID NOS: 1 to 5. The nucleic acid molecule according to the present invention may be a nucleic acid having an ability to bind to a rabbit IgG antibody, which substantially has homology to its sequence. The nucleic acid molecule according to the present invention may have a binding constant (K | 09-02-2010 |
20100222560 | UNIVERSAL COLUMN - A universal column is provided which allows purification methods utilizing centrifugation, syringe coupling and/or use of a vacuum source. Methods for using the universal column and kits comprising the universal column are described. | 09-02-2010 |
20100261890 | METHOD FOR THE CHEMICAL SYNTHESIS OF OLIGONUCLEOTIDES - The present invention features novel compositions, linkers, derivatized solid supports, and methods for the efficient solid phase synthesis of oligonucleotides, including RNA, DNA, RNA-DNA chimeras, and analogs thereof. | 10-14-2010 |
20100261891 | NUCLEIC ACID ANCHORING SYSTEM COMPRISING COVALENT LINKAGE OF AN OLIGONUCLEOTIDE TO A SOLID SUPPORT - The anchoring system generally comprises a solid support and a chemical linking moiety useful for ether formation with another chemical moiety on a nucleic acid molecule. The present invention further contemplates methods for anchoring a nucleic acid molecule to a solid support via a covalent linkage. The anchoring system of the present invention is useful inter alia in construction of nucleic acid arrays, to purify nucleic acid molecules and to anchor nucleic acid molecules so that they can be used as templates for in vitro transcription and/or translation experiments and to participate in amplification reactions. The present invention is particularly adaptable for use with microspheres and the preparation of microsphere suspension arrays and optical fiber arrays. The anchoring system permits the generation of an anchored oligonucleotide for use as a universal nucleic acid conjugation substrate for any nucleic acid molecule or population of nucleic acid molecules. The present invention further provides a kit useful for anchoring nucleic acid molecules or comprising nucleic acid molecules already anchored to a solid support. | 10-14-2010 |
20100286377 | BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE - Methods of binding biomolecules to a substrate are provided that include contacting the biomolecule with a branched linking moiety to form a branched linking structure. The branched linking structure is then contacted with a binding moiety on the substrate to form a coupled substrate binding structure, thereby binding the biomolecule to the substrate. The biomolecule may contain a Lewis base or a nucleophile to react with a Lewis acid or electrophile in the branched linking moiety. Alternatively, the biomolecule may contain a Lewis acid or electrophile that can react with a Lewis base or nucleophile in the branched linking moiety. Additionally, the biomolecule can be bound to the substrate through a covalent or non-covalent bond. | 11-11-2010 |
20100286378 | Composition of Asymmetric RNA Duplex As MicroRNA Mimetic or Inhibitor - The present invention provides double-stranded RNA molecules that are asymmetrical in strand length. The RNA molecule of the invention, the asymmetric RNA duplex, has one or two overhangs at the end. In one aspect, these novel RNA duplex molecules serve as effective mimetics of miRNA. In another aspect, they are designed to function as effective inhibitors of miRNA. Accordingly, the RNA molecules of the present invention can be used to modulate miRNA pathway activities, with tremendous implications for research, drug discovery and development, and treatment of human diseases. | 11-11-2010 |
20100286379 | BISULPHITE TREATMENT OF RNA - The invention relates to a method for bisulphite treating RNA comprising reacting RNA with a bisulphite reagent at 50-90° C. for 5-180 minutes so as to form treated RNA and recovering the treated RNA. | 11-11-2010 |
20100286380 | PRETREATMENT METHOD FOR EXTRACTION OF NUCLEIC ACID FROM BIOLOGICAL SAMPLES AND KITS THEREFOR - The present invention relates to methods for pretreating biological samples for extraction of nucleic acid therefrom. The present invention employs a combination of at least one protein denaturant with one or more of the following elements to form a reaction mixture for extraction of nucleic acid: (1) at least one aprotic solvent, (2) stepwise heating, and (3) sample dilution. | 11-11-2010 |
20100286381 | DIAGNOSTIC METHOD FOR CANCER CHARACTERIZED IN THE DETECTION OF THE DELETION OF G-CSF EXON 3 - Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker. | 11-11-2010 |
20100286382 | DISPOSABLE LABORATORY IMPLEMENT - A method of processing a liquid sample containing an initial quantity of nucleic acids that involves providing a plastic, disposable laboratory implement having at least one transparent wall segment made of a polypropylene mixed with an amount of a clarifier additive that is at least twice as high as is necessary to obtain transparency in the polypropylene, wherein the transparent wall segment exhibits a surface gloss greater than 160 as measured per DIN 67530 at an angle of 60°, bringing the liquid sample into contact with the at least one transparent wall segment and removing the liquid sample from the at least transparent wall segment, wherein the nucleic acid adsorption ratio for the transparent wall segment is less than 3 (wt/wt) relative to relative to the initial quantity of nucleic acids in the liquid sample. | 11-11-2010 |
20100292451 | METHOD FOR DIAGNOSING SELECTED ADENOCARCINOMAS - A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis. | 11-18-2010 |
20100292452 | Modified nucleotides - The invention provides modified nucleotide or nucleoside molecule comprising a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3′-OH blocking group covalently attached thereto, such that the 3′ carbon atom has attached a group of the structure —O—Z wherein Z is any of —C(R′)2-O—R″, —C(R′)2-N(R″)2, —C(R′)2-N(H)R″, —C(R′)2-S—R″ and —C(R′)2-F, wherein each R″ is or is part of a removable protecting group; each R′ is independently a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl, cyano, alkoxy, aryloxy, heteroaryloxy or amido group, or a detectable label attached through a linking group; or (R′)2 represents an alkylidene group of formula ═C(R′″)2 wherein each R′″ may be the same or different and is selected from the group comprising hydrogen and halogen atoms and alkyl groups; and wherein said molecule may be reacted to yield an intermediate in which each R″ is exchanged for H or, where Z is —C(R′)2-F, the F is exchanged for OH, SH or NH2, preferably OH, which intermediate dissociates under aqueous conditions to afford a molecule with a free 3′OH; with the proviso that where Z is —C(R′)2-S—R″, both R′ groups are not H. | 11-18-2010 |
20100298551 | Methods Of Producing And Sequencing Modified Polynucleotides - The present invention encompasses methods for producing a modified polynucleotide sequence that comprises a (e.g., one or more) phosphorothiolate linkage, methods for determining a polynucleotide sequence comprising a (e.g., one or more) phosphorothiolate linkage, and methods for separating forward and reverse extension products that comprise a (e.g., one or more) phosphorothiolate linkage. The invention also encompasses kits for producing and/or determining the sequence of a modified polynucleotide that comprises a (e.g., one or more) phosphorothiolate linkage. | 11-25-2010 |
20100298552 | EMULSION COMPOSITIONS - An emulsion is useful in allowing a wide variety of gene products to be expressed via eukaryotic in vitro expression. The emulsion comprises a silicone based surfactant, a hydrophobic phase and a hydrophilic phase; wherein the hydrophilic phase comprises a plurality of compartments containing a functional in vitro eukaryotic expression system. | 11-25-2010 |
20100311957 | Families of Non-Cross-Hybridizing Polynucleotides for Use as Tags and Tag Complements, Manufacture and Use Thereof - A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 1168 24mers is described. | 12-09-2010 |
20100311958 | CARRIER, METHOD AND REAGENT FOR OBTAINING SMALL RNA - An object of the present invention is to provide a carrier which enables to obtain a small RNA in high yield yet in high purity, a simple method for obtaining a small RNA and/or a target nucleic acid of small RNA using the same, and a reagent and a kit comprising the above-described carrier. | 12-09-2010 |
20100317839 | TP EXPRESSION-INHIBITING COMPOUND AND SIRNA SEQUENCE THEREOF - The present invention discloses a TP expression-inhibiting compound and a TP expression-inhibiting siRNA sequence, wherein a siRNA sequence partially or completely complementary to the sequence of TP is used to inhibit TP expression, whereby is effectively reduced the survival rate of cancer cells in an anoxic environment. | 12-16-2010 |
20100331532 | Use Of N-Alkyl Imidazole For Sulfurization Of Oligonucleotides With An Acetyl Disulfide - A method and compositions for sulfurizing at least one phosphite or thiophosphite linkage in an oligonucleotide. The addition of N-alkyl imidazole to the acetyldisulfide sulfurization solution enables the use of industrially preferred solvents or solvents that are derived from renewable resources. | 12-30-2010 |
20100331533 | Use Of Thioacetic Acid Derivatives In The Sulfurization Of Oligonucleotides With Phenylacetyl Disulfide - A method and compositions for sulfurizing at least one phosphite or thiophosphite linkage in an oligonucleotide. The methods employ a phenylacetyl disulfide reagent (known as PADS), phenylthioacetic acid (PTAA) in the presence or absence or N-alkyl imidazole in industrially preferred solvents or solvents that are derived from renewable resources. The use of PTAA eliminates the need to “age” the PADS solution prior to its use in sulfurization reactions. | 12-30-2010 |
20100331534 | NUCLEIC ACID PURIFICATION METHOD - The invention provides an modified method for the separation of nucleic acids from cells, comprising: generating an aqueous solution containing the nucleic acid by lysing the cells with a lysis solution including SDS and salt; and separating the nucleic acids of interest from other cellular components. The improvement includes adding a non-ionic detergent in the lysis solution such that SDS is not precipitated and no heating of the solution is required prior to cellular lysis. The preferred non-ionic detergents are the polysorbate family of compound, including TWEEN® 20. Also disclosed are composition and kit for performing the modified method. | 12-30-2010 |
20110015379 | METHOD AND KIT FOR PREPARATION OF SAMPLE FOR USE IN NUCLEIC ACID AMPLIFICATION - The object is to remove substances that can inhibit nucleic acid amplification from biological samples and nucleic acid extracts, and to allow convenient and accurate evaluation of the presence or absence of a target nucleic acid or the expression level of a target gene in a biological sample, by nucleic acid amplification means employing an enzyme. The invention provides a method for preparation of a sample for use in nucleic acid amplification, to be used for amplification of nucleic acid in a biological sample, which method comprises an extraction step in which a nucleic acid extraction reagent is added to the biological sample to obtain a nucleic acid extract, and a purification step in which the nucleic acid extract is contacted with zeolite to obtain a nucleic acid amplification sample suitable for nucleic acid amplification, to allow nucleic acid detection at high sensitivity. | 01-20-2011 |
20110015380 | Systems, Compositions And Methods For Nucleic Acid Detection - The invention relates to stretch measurements of nucleic acids and correlating those measurements to the extent of double- and single-stranded content of a nucleic acid of interest, and to compositions, systems, and devices related thereto. In preferred embodiments, one performs the stretch or elasticity measurements under conditions such that one can determine a nucleic acid sequence or the presence of an oligonucleotide in a sample. | 01-20-2011 |
20110028703 | METHOD AND APPARATUS FOR SUSPENDING MAGNETIC MICROPARTICLES - A method includes applying ultrasound to a container having a plurality of magnetic particles contacted with a fluid sample having a biological material capable of binding to the magnetic particles, in an amount effective to suspend the magnetic particles in the fluid. | 02-03-2011 |
20110034680 | MICROGININ PRODUCING PROTEINS AND NUCLEIC ACIDS ENCODING A MICROGININ GENE CLUSTER AS WELL AS METHODS FOR CREATING NOVEL MICROGININS - The invention provides for nucleic acid molecules enabling the synthesis of microginin and microginin analogues. The invention also provides for methods for identifying microginins as well creating microginins which may not be found in nature. | 02-10-2011 |
20110046359 | REVERSIBLE TERMINATOR NUCLEOTIDES AND METHODS OF USE - Disclosed herein a reversible terminator nucleotides and methods of use. | 02-24-2011 |
20110054157 | METHODS OF OPTIMAL PURIFICATION OF NUCLEIC ACIDS AND KIT FOR USE IN PERFORMING SUCH METHODS - A method and kit which allow the use of a discrete amount of a binding matrix to first purify nucleic acids from a medium under a first set of binding conditions wherein the amount of nucleic acid bound to the binding matrix is essentially independent of the amount of surface area of the definable amount of the binding matrix, followed by a second purification step wherein the nucleic acids are bound to a discrete amount of binding matrix under a second set of binding conditions wherein the amount of nucleic acid bound to the binding matrix is essentially dependent on the amount of surface area of the definable amount of the binding matrix, thus providing a discrete quantity of nucleic acid. | 03-03-2011 |
20110060135 | Selective Purification of Small RNAs from Mixtures - Methods and kits are provided for obtaining small RNAs from a mixture of RNAs of varying sizes such as can be found in a cell lysate or an enzyme-digested RNA. The methods and kits utilize magnetic beads and require the addition of one or more alcohols to bind small RNAs effectively to the beads. | 03-10-2011 |
20110060136 | DENDRIMER-COATED MAGNETIC FINE PARTICLES, AND METHOD FOR PREPARING SAME AND UTILITY THEREOF - Dendrimer-coated magnetic fine particles comprise magnetic fine particles, a lipid bilayer covering a surface of individual magnetic fine particles, and a dendrimer bound to an outer layer of the lipid bilayer. With the dendrimer-coated magnetic fine particles, the dendrimer is positively charged are brought into contact with a nucleic acid-containing solution to adsorb the nucleic acid on the dendrimer, while the nucleic acid-adsorbed fine particles are collected by magnetic force to recover the nucleic acid from the solution. | 03-10-2011 |
20110060137 | STOOL SAMPLE PROCESSING METHOD AND STOOL SAMPLE PROCESSING CONTAINER - The present invention relates to a stool sample processing method and stool sample processing container the a stool sample processing container provided with a stool collection tool, a suspending solution holding portion and a processing solution holding portion, wherein stool sample preparation solutions consisting of a suspending solution and a stool sample processing solution are respectively housed in a suspending solution holding container and a processing solution holding container, after first mixing a stool sample with the suspending solution and suspending therein, a sealant is released into the suspending solution holding container by pressing on the lower portion of the processing solution holding container, and the resulting stool suspension mixes with the stool sample processing solution that stabilizes the nucleic acid. | 03-10-2011 |
20110065906 | COMPOSITIONS AND METHODS FOR RECOVERY OF NUCLEIC ACIDS OR PROTEINS FROM TISSUE SAMPLES FIXED IN CYTOLOGY MEDIA - The present invention provides compositions and methods for improving nucleic acid or protein recovery from fixed biological samples. | 03-17-2011 |
20110065907 | Methods and compositions for labeling nucleic acids - The present invention relates to methods for the labeling of nucleic acid polymers in vitro and in vivo. In particular, the methods include a [3+2] cycloaddition between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent attached to a label. Such methods do not require fixation and denaturation and therefore can be applied to the labeling of nucleic acid polymers in living cells and in organisms. Also provided are methods for measuring cellular proliferation. In these methods, the amount of label incorporated into the DNA is measured as an indication of cellular proliferation. The methods of the invention can be used in a wide variety of applications including clinical diagnosis of diseases and disorders in which cellular proliferation is involved, toxicity assays, and as a tool for the study of chromosomes' ultrastructures. | 03-17-2011 |
20110082286 | Method for Generating Aptamers with Improved Off-Rates - The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element. | 04-07-2011 |
20110087013 | Friedel-Crafts acylation for the synthesis of aryl- and heteroaryl-(3-ethyl-4-nitrophenyl)-methanones - The present invention concerns a synthesis process comprising the following steps (i) reacting 3-ethyl-4-nitrobenzoic acid with thionyl chloride to produce a 3-ethyl-4-nitrobenzoic acid chloride or a 3-ethyl-4-nitrobenzoic acid anhydride from 3-ethyl-4-nitrobenzoic acid by means of water cleavage and (ii) Friedel-Crafts acylation by reacting the 3-ethyl-4-nitrobenzoic acid chloride or the 3-ethyl-4-nitrobenzoic acid anhydride with an optionally substituted aryl-H to form an optionally substituted (3-ethyl-4-nitrophenyl)-aryl-methanone. In addition the present invention concerns compounds containing (3-ethyl-4-nitrophenyl)-aryl-methanone, characterized in that the optionally substituted aryl is an optionally substituted condensed aromate. | 04-14-2011 |
20110087014 | Process for the manufacture of oligonucleotides - A process for manufacturing an oligonucleotide which comprises removing β-eliminating phosphorus-protecting groups, in particular β-cyanoethyl protective groups from a protected oligonucleotide, wherein said removing comprises contacting the protected oligonucleotide with an amine solution in a solvent which preferably does not consist of pyridine, wherein the conjugate acid of the amine has preferably a pKa of greater than 11.5, and wherein the concentration of the amine in the solution is less than 0.5 mole/liters. | 04-14-2011 |
20110092685 | AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID - To provide an excellent amidite for synthesizing modified nucleic acid, which enables a protective group therein to be removed under a moderate condition, thereby stably producing a hydroxyl group-containing modified nucleic acid, and a method for synthesizing modified nucleic acid using the amidite. Specifically, an amidite for synthesizing modified nucleic acid, expressed by General Formula (I): | 04-21-2011 |
20110092686 | MULTICAPILLARY SAMPLE PREPARATION DEVICES AND METHODS FOR PROCESSING ANALYTES - Disclosed herein are sample preparation devices, such as pipette tips and pipette tip extenders, for example, useful for associating and releasing analytes. | 04-21-2011 |
20110092687 | STABLE LYSIS BUFFER MIXTURE FOR EXTRACTING NUCLEIC ACIDS - The invention relates to a lysis buffer mixture that is stable in storage for isolating nucleic acids from biological, preferably diagnostic samples. The mixture is preferably associated with an extraction control. The aim of the invention is to provide an improved nucleic acid extraction system, which is cost-effective, stable and easy to use, thus fulfilling the requirements of a modern nucleic acid extraction system and containing, among other things, extraction controls. The invention relates to a lysis buffer mixture for isolating nucleic acids, said mixture containing non chaotropic salts, a special selection of detergents, a defined quantity of at least one nucleic acid as an extraction control, optionally lytic enzymes, optionally carrier nucleic acids and optionally other additives. | 04-21-2011 |
20110098456 | IMMUNE STIMULATORY OLIGONUCLEOTIDE ANALOGS CONTAINING MODIFIED SUGAR MOIETIES - The invention relates to oligonucleotides including at least one FANA substituted nucleotide analog and a pyrimidine-purine dinucleotide. The invention also relates to pharmaceutical compositions and methods of use thereof. | 04-28-2011 |
20110098457 | METHODS OF ATTACHING BIOLOGICAL COMPOUNDS TO SOLID SUPPORTS USING TRIAZINE - Disclosed are methods of attaching biologically active compounds to a solid surface, comprising modifying the solid surface using triazine chloride and attaching the biologically active compound to the triazine moiety. | 04-28-2011 |
20110105739 | NOVEL MATRIX MATERIALS, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF IN METHODS FOR ISOLATING BIOMOLECULES - The invention relates to functionalized matrix materials or matrices that have structures of general formula (I) T-(C═O)O—B-D, methods for the production thereof, and the use thereof in methods for purifying and isolating biomolecules. | 05-05-2011 |
20110105740 | SOLUBLE TNF RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE - The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist. | 05-05-2011 |
20110118454 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED - The invention concerns a method for preparing monomer nucleotides or nucleotide analogues comprising the steps of: (1) coupling a soluble polyethylene glycol support provided with at least one diacid or ether-acid linker and a monomer nucleoside or nucleoside analogue to an amine group or hydroxyl group of the nucleoside with the aid of a coupling agent; (2) at least one step for phosphorylation of said nucleoside or nucleoside analogue coupled to said support with a phosphorylation agent; (3) cleavage of said support and recovery of at least one monomer nucleotide or nucleotide analogue. The nucleotides prepared are biological tools. | 05-19-2011 |
20110118455 | PROTECTING GROUP FOR INDOLE GROUP, NUCLEIC ACID-SYNTHESIZING AMIDITE AND NUCLEIC ACID-SYNTHESIZING METHOD - A protecting group for 1-nitrogen atom of an indole group including a sulfonylethyl carbamate group, wherein the protecting group is represented by the following General Formula (I) and capable of being removed from the 1-nitrogen atom of the indole group in an aprotic solvent: | 05-19-2011 |
20110124851 | Method of Isolation of Nucleic Acids - A method of isolation of nucleic acids from a biological sample of cells comprising a combination of a solid phase cell nuclei isolation procedure with a solid phase nucleic acid isolation method. | 05-26-2011 |
20110124852 | MOLECULAR MARKERS FOR IDENTIFICATION OF FAT AND LEAN PHENOTYPES IN CHICKENS - The invention provides molecular methods of screening chickens to determine those more likely to have a lean or fat phenotype by identifying the presence of at least one polymorphism in genetic material of a chicken in the thyroid hormone repressible gene (THRG) or its 3′ untranslated region (SEQ ID NO: 1) that is associated with a fat phenotype or a lean phenotype. The invention also provides methods of screening chickens to identify a polymorphism associated with a fat or lean phenotype. The invention further provides oligonucleotide probes and primers useful for detecting the polymorphisms associated with a fat or lean phenotype. | 05-26-2011 |
20110152510 | SIMPLE LOAD AND ELUTE PROCESS FOR PURIFICATION OF GENOMIC DNA - Provided is a novel two step chromatographic purification process (load and elute) for the isolation of genomic DNA. In this method the sample is loaded on the column and the genomic DNA product is eluted directly without any intermediate wash steps. This is accomplished by utilizing a restricted access resin (i.e., lid beads), which is easy to prepare and comprised of two layers with different properties with non-functional surfaces on the outer layer. The inner layer is modified with functional groups that act as ion-exchangers. Small molecules such as RNA and proteins can enter the inner part of the resin and larger genomic DNA molecules will pass through the resin. RNA and proteins are captured in the inner layer of the restricted access resin while genomic DNA is readily eluted in the flow-through. | 06-23-2011 |
20110160443 | RNA APTAMERS AND METHODS FOR IDENTIFYING THE SAME - RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed. | 06-30-2011 |
20110172403 | Microfluidic Device Including Purification Column with Excess Diluent and Method - Methods, apparatus, and a system are provided for processing a sample in a fluidic device. The device can include a purification column, an entrance opening to the purification column, an output reservoir, a fluid communication between the purification column and the output reservoir, and an openable and recloseable valve capable of interrupting fluid flow through the fluid communication. Methods of processing samples using such a device are also provided. | 07-14-2011 |
20110172404 | Self-Assembly of Nanoparticles Through Nuclei Acid Engineering - A self-assembly nanodevice formed through nucleic acid engineering is disclosed. The nanodevice may include an array of nanoparticles. The nanodevice may further include a substrate that supports the array of nanoparticles. Each of the nanoparticles may be coordinated with a plurality of nucleic acids that are substantially free of Watson-Crick base-paring with nucleic acids coordinated with other nanoparticles. Methods of forming the nanodevice, as well as the microscopic organization of the nanoparticles are also disclosed. By manipulating the nucleic acids as capping ligands, the inter-particle distance may be extended to a greater range than nanotechnology based on alkyl ligands or nucleic acids base-pairing. | 07-14-2011 |
20110172405 | METHOD FOR SMALL RNA ISOLATION - This invention relates to a simple and rapid method for the extraction and purification of small RNA from a sample solution. Accordingly, a sample is first mixed with an organic solvent to form a mixture containing the solvent. The mixture is applied to a first mineral support for large RNA to bind. The filtrate is collected which contain unbound small RNA, and is mixed with a second organic solvent to form a second mixture containing the second solvent. This second mixture is applied to a second mineral support for small RNA to bind. After a wash step, the small RNA is eluted. Also provided is a method for the isolation of large RNA, by eluting the large RNA from the first mineral support. In addition, total protein is present in the filtrate and can be isolated by a conventional method. | 07-14-2011 |
20110178281 | Photocleavable Linker Methods and Compositions - Bifunctional linkers are provided that comprise a photocleavable moiety flanked by two different amine reactive moieties. In some embodiments the photocleavable moiety is a dimethoxynitrobenzyl moiety. In other embodiments the photocleavable moiety is 8-bromo-7-hydroxyquinoline. In other embodiments the photocleavable moiety is nitrodibenzofuran. In other embodiments the photocleavable moiety is 6-bromo-7-hydroxycoumarin-4-ylmethyl. The linkers find use in synthetic methods, including the generation of photocleavable oligonucleotides, e.g. caged morpholinos. | 07-21-2011 |
20110184160 | NUCLEIC ACID MOLECULE ENCODING CONSENSUS INFLUENZA A HEMAGGLUTININ H1 - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotpyes using the vaccines that are provided. | 07-28-2011 |
20110184161 | USE OF MICROARRAYS FOR GENOMIC REPRESENTATION SELECTION - The present invention provides novel methods for reducing the complexity of a genomic sample for further analysis such as direct DNA sequencing, resequencing or SNP calling. The methods use pre-selected immobilized oligonucleotide probes to capture target nucleic acid molecules from a sample containing denatured, fragmented genomic nucleic acid. The disclosed method provides for cost-effective, flexible and rapid enrichment of target nucleic acid from complex biological samples. | 07-28-2011 |
20110190482 | POLYMER ENCAPSULATED ALUMINUM PARTICULATES - The present invention relates to use of novel bioinformatics approach for predicting and identifying Scaffold/Matrix attachment regions (S/MARs) from different genomic database. | 08-04-2011 |
20110190483 | Stimulus-Responsive Apta Chelamers - Disclosed are apta-chelamers comprising aptamer domains tethered to rationally designed synthetic protein-binding modules, and methods of designing and making the same. Also disclosed are stimulus-responsive apta-chelamers capable of simultaneously or sequentially binding (and, thus, inhibiting) two protein targets. | 08-04-2011 |
20110196141 | LOCKED AND UNLOCKED 2'-O PHOSPHORAMIDITE NUCLEOSIDES, PROCESS OF PREPARATION THEREOF AND OLIGOMERS COMPRISING THE NUCLEOSIDES - The present invention relates to 2′-O-phosphoramidite of locked nucleoside and unlocked nucleoside, their synthesis and 2′-5′-linked oligomers oligomers comprising the nucleosides to delineate the structural requirements of 2′-5′ RNA/DNA: 3′-5′ RNA duplexes and also for use in antisense applications. | 08-11-2011 |
20110196142 | DNA molecule for expressing Hairpin RNA, the constructing method and the use thereof - DNA molecule for expressing hairpin RNA, the constructing method and the use thereof are provided. The DNA molecule is a closed single-strand cyclic DNA molecule which is constructed by linking four fragments A, B, C and D as following order: A-C-B-D or A-D-B-C, wherein A is a sense strand or anti-sense strand fragment of the target double-strand DNA; B is the fragment which is reversely complementary to A; C and D are DNA fragments with stem-loop structure and they meet one of the following requirements: 1) the nucleotide sequence of fragment C or D comprises at least one sequence e; 2) the nucleotide sequence of fragment C comprises at least one sequence e, the nucleotide sequence of fragment D comprises at least one sequence f, wherein sequences e and f individually are one strand of different restriction endonuclease recognition sequences. The DNA molecule for expressing hairpin RNA and its constructing method are useful in constructing lhRNA library. | 08-11-2011 |
20110201796 | DNA sequence in plant caragana jubata with freeze tolerance - An isolated DNA sequence set forth in SEQ ID NO: 32, which is differentially expressed in apical buds of plant | 08-18-2011 |
20110201797 | Nucleic Acid Shearing Device with Disposable Cartridge - Apparatus, devices, and methods for shearing nucleic acids are provided. In one exemplary embodiment the device is a disposable nucleic acid shearing cartridge. The cartridge includes two reservoirs, an orifice structure disposed therebetween, and a fluid driver. The reservoirs are in fluid communication with each other by way of the orifice structure, and the fluid driver cycles a sample between the two reservoirs. By passing a sample from one reservoir to the next, through the orifice structure, an orifice located in the orifice structure can shear the sample to a desired length. The sheared sample can then be used, for example, in a sequencing device. Apparatuses for cycling samples in the cartridge, and methods and kits for shearing nucleic acids, are also disclosed. | 08-18-2011 |
20110213135 | Cytotoxic Nucleotides for Targeted Therapeutics - The present invention provides a method of generating a nucleic acid, which specifically binds to an extracellular surface protein expressed by a cell of interest, and which nucleic acid comprises a compound of interest to be delivered to the cell of interest. | 09-01-2011 |
20110218332 | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof - The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of weight, and to the diagnostic and therapeutic uses to which such modulators may be put. In its broadest aspect, the present invention relates to the elucidation and discovery of nucleotide sequences, and proteins putatively expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The nucleotide sequences in object represent the genes corresponding to the murine and human ob gene, that have been postulated to play a critical role in the regulation of body weight and adiposity. Preliminary data, presented herein, suggests that the polypeptide product of the gene in question function as a hormone. The present invention further provides nucleic acid molecules for use as molecular probes, or as primers for polymerase chain reaction (PCR) amplification, i.e., synthetic or natural oligonucleotides. In further aspects, the present invention provides a cloning vector, which comprises the nucleic acids of the invention; and a bacterial, insect, or a mammalian expression vector, which comprises the nucleic acid molecules of the invention, operatively associated with an expression control sequence. Accordingly, the invention further relates to a bacterial or a mammalian cell transfected or transformed with an appropriate expression vector, and correspondingly, to the use of the above mentioned constructs in the preparation of the modulators of the invention. Also provided are antibodies to the ob polypeptide. Moreover, a method for modulating body weight of a mammal is provided. In specific examples, genes encoding two isoforms of both the murine and human ob polypeptides are provided. | 09-08-2011 |
20110224415 | HUMAN MUTY - A human mutY polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating diseases associated with a mutation in this gene. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed. | 09-15-2011 |
20110230653 | STABILIZATION OF NUCLEIC ACIDS ON SOLID SUPPORTS - The present invention provides methods, compositions, and kits for the storage and stabilization of biological molecules. The methods comprise applying Tris(2-carboxyethyl)phosphine (TCEP) to at least one biological molecule bound to a solid substrate and storing in an organic solvent. Preferably, the biological molecules are nucleic acids. Compositions and kits for performing the process according to the invention are also provided. | 09-22-2011 |
20110237786 | METHOD FOR PREPARING OLIGONUCLEOTIDE - A method for preparing oligonucleotide comprising reacting the compound of Formula (1) with the compound of Formula (2) in a liquid reaction medium under the condition of condensation reaction to obtain the compound of formula (3). In the method according to the present invention, the functional groups are protected by suitable protective groups to only expose the 5′-OH of the compound of Formula (1) (OH-component) and the 3′-phosphate of the compound of Formula (2) (P-component) which are to be connected, so that the condensation reaction is carried out in a liquid reaction medium to bond the OH-component and P-component to obtain DNA or RNA short chain. The method of the present invention does not need a solid phase column and can be carried out in a liquid reaction medium. Thus, oligonucleotides can be synthesized on a large scale. | 09-29-2011 |
20110245479 | Method for Generating Aptamers with Improved Off-Rates - The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element. | 10-06-2011 |
20110251382 | ISOLATION OF NUCLEIC ACID - The present invention provides a method of isolating nucleic acid from a sample, said method comprising contacting said sample with a detergent and a solid support, whereby soluble nucleic acid in said sample is bound to the support, and separating said support with bound nucleic acid from the sample. Where the method of the invention is used to isolate DNA, it may conveniently be couple with a further step to isolate RNA from the same sample. | 10-13-2011 |
20110257382 | Nucleic acid separation using immobilized metal affinity chromatography - An immobilized metal affinity chromatography (IMAC) method for separating and/or purifying compounds containing a non-shielded purine or pyrimidine moiety or group such as nucleic acid, presumably through interaction with the abundant aromatic nitrogen atoms in the purine or pyrimidine moiety. The method can also be used to purify compounds containing purine or pyrimidine moieties where the purine and pyrimidine moieties are shielded from interaction with the column matrix from compounds containing a non-shielded purine or pyrimidine moiety or group. Thus, double-stranded plasmid and genomic DNA, which has no low binding affinity can be easily separated from RNA and/or oligonucleotides which bind strongly to metal-charged chelating matrices. IMAC columns clarify plasmid DNA from bacterial alkaline lysates, purify a ribozyme, and remove primers and other contaminants from PCR reactions. The metal ion affinity of yeast RNA decreases in the order: copper (II), nickel (II), zinc (II), and cobalt (II). | 10-20-2011 |
20110257383 | RNA COMPLEXES, METHODS OF THEIR PRODUCTION - The invention includes RNA complexes comprising at least three monomeric units of an RNA molecule, each monomeric unit comprising an RNA polymer having first and second helical domains that have respective first and second binding sites, wherein the first binding sites are adapted to binding to one another and are not adapted to bind to the second binding sites, and the second binding sites are adapted to binding to one another and are not adapted to bind to the first binding sites; such that the at least three monomeric units are adapted to self-assemble by forming pairs of cognate interactions and so as to form the RNA complex in a circular closed complex. The invention also includes derivatives of these complexes including aptamers, and analytical methods and devices using same. | 10-20-2011 |
20110263838 | MULTICAPILLARY DEVICE FOR SAMPLE PREPARATION - A multicapillary sample preparation device, especially useful for handling biological samples, comprising a plurality of uniform capillary tubes coated with a stationary phase, and arranged in a monolithic element. The multicapillary device is suitable for attachment to a pipette, micropipette, syringe, or other analytical or sample preparation instrument. | 10-27-2011 |
20110269948 | Method for Identifying Compounds for Cancer Therapy - The present invention relates to an in vitro method for identifying and evaluating compounds useful in the treatment of different types of cancer, especially lung, breast, colorectal and bladder cancer in an individual, for determining the stage or severity of said cancer in the individual, or for monitoring the effect of the therapy administered to an individual having said cancer; to finding, identifying, developing and evaluating the efficacy of compounds for the therapy of said cancer, for the purpose of developing new medicinal products; as well as to agents inhibiting the expression and/or activity of the choline kinase alpha protein and/or the effects of this expression. | 11-03-2011 |
20110275793 | Chemical RNA Synthesis Method - The invention relates to a method for the chemical synthesis of RNA, comprising the following steps: a) bonding to a solid support of a monomer having formula (II) in which—X | 11-10-2011 |
20110275794 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE - The present disclosure relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines as well as phosphoramidite and triphosphate derivatives thereof. The present disclosure also relates to methods of making and using the same. | 11-10-2011 |
20110282043 | METHODS AND COMPOSITIONS COMPRISING NUCLEIC ACID POLYMERIZATION ENHANCERS - Embodiments of the invention are directed to compositions and methods that use non-extendable oligonucleotides to enhance or improve synthesis or amplification of nucleic acids. | 11-17-2011 |
20110288284 | METHODS AND COMPOSITIONS FOR ISOLATING POLYNUCLEOTIDES - Methods of isolating target double-stranded polynucleotides with internal single-stranded regions are provided. Compositions and kits comprising double-stranded polynucleotides with internal single-stranded regions are also provided | 11-24-2011 |
20110294995 | Functionalized nanoparticles and other particles and methods for making and using same - Disclosed are nanoparticles which include a nanoparticle core having a core diameter of greater than 5 nm and a single functional moiety bonded to the nanoparticle core. Also disclosed are nanoparticles which include a nanoparticle core having a core diameter of greater than 1.4 nm and a single functional moiety bonded to the nanoparticle core, wherein the single functional moiety does not contain a nucleic acid molecule that includes 100 or more nucleotides. A method for preparing a functionalized nanoparticle is also disclosed. The method includes providing a nanoparticle core and providing a functionalizing moiety that includes a functional group and a reactive group. The functional group is attached to a substrate surface, and the reactive group is capable of bonding to the nanoparticle core's surface. The method further includes contacting the nanoparticle core's surface with the functionalizing moiety under conditions effective to bind the functionalizing moiety's reactive group and the nanoparticle core's surface together. | 12-01-2011 |
20110294996 | QUANTUM UNIT OF INHERITANCE - Quantum genes have a unique identifier assigned to them. By identifying genetic material with a unique identifier a means of locating specific genetic material is plausible. Delivering such quantum genes, that contain a unique identifier, to specific cell types provides a means of inserting specific genetic information into the cell's nuclear deoxyribonucleic acid that can be readily located by the cell's nuclear transcription complexes. These medically therapeutic quantum genes are intended to provide a wide variety of medical therapeutic options to clinicians. | 12-01-2011 |
20110306758 | METHOD AND MATERIALS FOR THE COOPERATIVE HYBRIDIZATION OF OLIGONUCLEOTIDES - A two-stranded intermediary complex and cooperative hybridization method are provided. The complex has been designed so that target oligonucleotides of independent sequence can cooperatively and simultaneously hybridize to it. The cooperative hybridization mechanism is robust and modular, smoothly integrating with other dynamic DNA components to form cascaded reaction networks that can perform a variety of functions. | 12-15-2011 |
20110313143 | NUCLEIC ACID PURIFICATION APPARATUS AND METHOD - Provided herein is a clarification/binding device for the isolation of at least one target molecule from a sample. The clarification/binding device can comprise an clarification column and a binding column. The clarification column can be configured to receive the sample. Further, the clarification column can comprise a filter configured to filter at least one non-target molecule from the sample. The binding column can be configured to receive the filtered sample from the clarification column. The binding column can comprise a binding material for binding at least one target molecule. The clarification/binding device can be configured to filter the sample and bind at least one target molecule under negative pressure. Further provided herein is an apparatus for the isolation of a target molecule from a sample. The apparatus can comprise a top plate and a vacuum manifold comprising a first chamber and a second chamber. The top plate can be configured to be used with one or both of the first vacuum chamber and the second chamber of the vacuum manifold. Further provided herein are methods of use of the clarification/binding device and the vacuum apparatus and kits comprising the clarification/binding device and vacuum apparatus. | 12-22-2011 |
20110319605 | PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN IMMOBILIZED OLIGONUCLEOTIDE - Method for double-stranded DNA purification, by which a solution containing said DNA in a mixture with other components is passed over a support on which is covalently coupled in oligonucleotide capable of hybridizing with a specific sequence present on said DNA to form a triple helix. | 12-29-2011 |
20110319606 | COMPOUNDS AND METHODS FOR LABELING OLIGONUCLEOTIDES - A compound having the general formula shown below: | 12-29-2011 |
20120010392 | PROTEIN KINASE-INDUCIBLE DOMAINS - Applicants have used protein design to develop novel functional protein architectures, termed protein kinase-inducible domains, whose structures are dependent on phosphorylation by specific protein kinases or are dependent on dephosphorylation by specific protein phosphatases. Applicants have designed kinase-inducible domains based on a modular architecture, which allows kinase-inducible domains to be responsive to any specific serine-threonine kinases. Kinase-inducible domains can consist of canonical amino acids, allowing their use as expressible tags of protein kinase activity. | 01-12-2012 |
20120010393 | 5'-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS - The present invention provides 5′-modified bicyclic nucleoside analogs and oligomeric compounds comprising at least one of these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 5′-carbon. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including for example enhanced nuclease resistance. | 01-12-2012 |
20120022243 | BIOMOLECULAR SELF-ASSEMBLY - The present invention relates generally to programming of biomolecular self-assembly pathways and related methods and constructs for self-assembly of prescribed two and three-dimensional structures. | 01-26-2012 |
20120022244 | SELF-ASSEMBLED POLYNUCLEOTIDE STRUCTURE - The present application provides polynucleotide structures such as nucleic acid ribbons and nucleic acid tubes, methods for making the polynucleotide structures, and methods for making two-dimensional or three-dimensional objects comprising the nucleic acid ribbons and nucleic acid tubes. | 01-26-2012 |
20120035353 | ALIGNED NANOSTRUCTURED POLYMERS - Novel, simple methods are presented directed to the synthesis of aligned nanofibers of polyaniline and substituted derivatives on a substrate. The production of these fibers is achieved via various methods by controlling the concentration of aniline monomer or substituted aniline derivatives or an oxidant in the reaction medium and maintaining said concentration at a level much lower than conventional polyaniline synthesis methods. Methods are disclosed relating to the use of a permeable membrane to control the release of a monomer and/or oxidant as well as a bulk polymerization method. | 02-09-2012 |
20120071639 | Methods and compositions of nucleic acid ligands for detection of foodborne and waterborne pathogens - Specific DNA sequences for binding various foodborne and waterborne pathogens and biotoxins are described. Each of these sequences can function in varying assay and sensor formats with varying degrees of success. | 03-22-2012 |
20120071640 | Sulfurizing reagents and their use for oligonucleotides synthesis - An oligonucleotide which comprises at least one internucleotide linkage comprising a P—S—R bond and at least two nucleosides, wherein R corresponds to the formula (I) | 03-22-2012 |
20120095200 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY NUCLEIC ACID CONTAINING A DICER SUBSTRATE AND A RECEPTOR BINDING REGION - The invention features compositions and methods that are useful for reducing the expression or activity of a specified gene in a eukaryotic cell, involving contacting a cell with an isolated nucleic acid containing a Dicer substrate and a receptor binding region in an amount effective to reduce expression of a target gene in a cell. | 04-19-2012 |
20120101267 | MULTICOMPONENT NUCLEIC ACID ENZYMES WITH CLEAVAGE, LIGASE OR OTHER ACTIVITY AND METHODS FOR THEIR USE - The present invention relates to Multicomponent Nucleic Acid Enzymes (MNAzymes) and methods for their use. MNAzymes comprise two or more oligonucleotide components which self-assemble in the presence of one or more MNAzyme assembly facilitator molecules to form a catalytically active structure which may have cleavage, ligase or other enzymatic activity. Compositions for making MNAzymes and collections of MNAzymes are provided, together with uses thereof. Also provided are methods for using MNAzymes for the detection, identification and/or quantification of one or more targets. The methods can be practiced in solution-based assays or in assays where one or more reaction components are attached to a support structure. The methods allow for multiplexing the MNAzyme detection to detect multiple targets in a single reaction. Also provided are kits for making the compositions, and for practicing the methods provided herein. | 04-26-2012 |
20120123105 | Gene Signature for Diagnosis and Prognosis of Breast Cancer and Ovarian Cancer - A first embodiment is a breast cancer prognosticator comprising a detection mechanism consisting a 15-gene signature. In addition there are embodiments comprised of 23-gene signatures and 28-gene signatures. The 28-gene signature may also be used for the prognosis of ovarian cancer. Another embodiment is a method to determine relapse free potential in breast cancer patients comprising collecting a sample from an individual, removing marker-derived polynucleotide from said sample, using a detection mechanism to search for positive matches of said polynucleotides and a 24-gene signature, and developing a quantitative expression profile. | 05-17-2012 |
20120123106 | METHOD FOR ISOLATING HIGH-PURITY RNA BY MEANS OF PARAMAGNETIC MICROPARTICLES AND NANOPARTICLES - The invention relates to a purification method for high-purity, DNA-free RNA using a mixture of nanocarrier beads and paramagnetic beads. | 05-17-2012 |
20120136143 | Methods and Kits for Sense RNA Synthesis - Methods and kits are provided for performing multiple rounds of sense RNA synthesis. The sense RNA molecules can be used in various research and diagnostic applications, such as gene expression studies involving nucleic acid microarrays. | 05-31-2012 |
20120149888 | SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS - The present invention relates to synthesis, purification and methods to obtain high purity novel 2′-arabino-O-methyl nucleosides and the corresponding phosphoramidites of various arabinonucleoside bases and introduction of such units into defined sequence synthetic DNA and RNA. Various synthetic oligonucleotides, such as HIV integrase inhibitor 14-mer and thrombin binding oligonucleotide, thrombin-1, bearing ara-2′-omethyl modification have been synthesized. It is anticipated the oligonucleotides incorporating these monomers will exhibit biological activities related to antisense approach approach, design of better SiRNA's, diagnostic agents. Similarly, it is anticipated that oligonucleotides incorporating such novel nucleosides will be useful to develop therapeutic candidates designing stable G-quadruplexes and Aptamers for oligonucleotide structure, folding topology, evaluation of biochemical properties and design and develop as therapeutic agents. It is further anticipated that the nucleosides, phosphates and triphosphates of this invention could develop as therapeutic agents. | 06-14-2012 |
20120149889 | Methods and compositions of DNA ligands for arthropod-borne pathogen detectionand prophylaxis or therapy - Specific DNA ligand sequences for binding various arthropod-borne pathogens including arboviruses, rickettsia and parasites are described. Each of these sequences or their linear, two- and three-dimesional linked sequences can function in varying assay and sensor formats with varying degrees of success. Linkage of the whole or partial DNA sequences (putative binding sites) can be used to enhance specificity and affinity towards complex targets, thereby improving assay selectivity and sensitivity in many instances. In addition, the DNA sequences may bind and neutralize or prevent infection from arthropod-borne viruses, rickettsia and Leishmania or other parasites. | 06-14-2012 |
20120157670 | Aptamer-based assays - We describe examples using aptamers for capturing and reporting the presence of a target, such as a pathogen. Examples described here include a set of aptamers that are specific to | 06-21-2012 |
20120172581 | PROCESS FOR THE IDENTIFICATION OF COMPOUNDS FOR TREATING CANCER - Process for the identification of compounds for treating cancer. The invention relates to a method for identifying candidate compounds for use as therapeutic agents for the treatment of cancer, among those who are able to activate the MDA-5 protein or increase NOXA protein levels and to trigger autophagy. It is based on the fact that activation of dsRNA sensor MDA-5 is able to trigger the destruction of cancer cells by activation both autophagy and apoptosis, autonomously and selectively in tumor cells, without provoking the stabilization of the natural antagonist NOXA, MCL-1. The invention also relates to the use of double-stranded RNAs of the same or similar nature such as polyinosinic-polycytidylic acid (pIC), complexed with carriers such as polyethylenimine polycation (PEI), for the manufacture of medicines for the treatment of cancer. | 07-05-2012 |
20120172582 | Labelling Strategies for the Sensitive Detection of Analytes - The present invention relates to methods and reagents for detecting analytes, e.g. nucleic acids. The new methods and reagents allow a simple and sensitive detection even in complex biological samples. | 07-05-2012 |
20120178917 | RNA APTAMERS AND METHODS FOR IDENTIFYING THE SAME - RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed. | 07-12-2012 |
20120184724 | PROTECTED MONOMERS AND METHODS OF DEPROTECTION FOR RNA SYNTHESIS - A nucleoside monomer that is protected by a thionocarbamate protecting group and contains one or more | 07-19-2012 |
20120184725 | Nucleic Acid Purification - Methods and composition for nucleic acid isolation are provided. In one embodiment, the invention provides a method for nucleic acid purification from biological samples extracted with phenol-based denaturing solvents, which does not require phase separation or nucleic acid precipitation. Methods according to the invention may also be used for differential isolation of RNA and DNA. | 07-19-2012 |
20120184726 | SHORT RNA MIMETICS - The present invention provides synthetic oligonucleotides that mimic the function of short RNAs such as, for example, microRNAs or short interfering RNAs. In particular, the synthetic oligonucleotides comprise a duplex region comprising an unpaired bulge in one of the strands. | 07-19-2012 |
20120190833 | METHOD OF SELECTION, BY TWO-DIMENSIONAL SEPARATION, OF NUCLEIC ACIDS THAT BIND TO A TARGET WITH HIGH AFFINITY - The invention relates to a method of selection, by two-dimensional separation, of nucleic acids that bind to a target molecule with high affinity from a mixture of nucleic acids, including the following steps: a) subjecting the mixture of nucleic acids to a physico-chemical separation step, thereby obtaining a set of mixed fractions containing the nucleic acids, a run parameter window being associated with every mixed fraction containing the nucleic acids, b) contacting a mixed fraction containing the nucleic acids with the target molecule, thereby obtaining a binding mixture containing nucleic acid/target molecule complexes, c) subjecting the binding mixture from step b) to the same physico-chemical separation step as in step a), thereby selecting nucleic acid/target molecule complexes whose run parameters are outside of the run parameter window. | 07-26-2012 |
20120190834 | APTAMERS TO TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE AS BLEEDING DISORDER THEREAPEUTICS - The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI. | 07-26-2012 |
20120190835 | HYBRIDIZATION CHAIN REACTION AMPLIFICATION FOR IN SITU IMAGING - The present invention relates to the use of fluorescently labeled nucleic acid probes to identify and image analytes in a biological sample. In the preferred embodiments, a probe is provided that comprises a target region able to specifically bind an analyte of interest and an initiator region that is able to initiate polymerization of nucleic acid monomers. After contacting a sample with the probe, labeled monomers are provided that form a tethered polymer. Triggered probes and self-quenching monomers can be used to provide active background suppression. | 07-26-2012 |
20120202981 | NOVEL GUANOSINE-RICH MODIFIED OLIGONUCLEOTIDES AND ANTIPROLIFERATIVE ACTIVITY THEREOF - The present invention relates to a novel modified oligonucleotide comprising at least one guanosine molecule and a modified nucleic acid with therapeutic efficacies. The present invention also relates to a pharmaceutical composition having cell apoptotic activity against cancer cells for preventing or treating cancer comprising a guanosine-rich modified oligonucleotide with at least one therapeutically effective modified nucleic acid (N), or its pharmaceutically acceptable salt as active ingredient. | 08-09-2012 |
20120208990 | HUMAN PLATELET F11 RECEPTOR - The present invention is directed to isolated nucleic acid molecules encoding human platelet F11 receptors. Expression vectors and host cells comprising the nucleic acid molecules are also provided, as well as methods for increasing or decreasing the expression of the human platelet F11 receptor in host cells. The invention further provides a method of screening a substance for the ability of the substance to modify human platelet F11 receptor function, and a method for isolating other human platelet F11 receptor molecules. DNA oligomers capable of hybridizing to the nucleic acid molecule encoding the human platelet F11 receptor are provided, which can be used to detect human platelet F11 receptor in a sample. | 08-16-2012 |
20120208991 | BRIDGED ARTIFICIAL NUCLEOSIDE AND NUCLEOTIDE - It is an object of the present invention to provide a novel molecule for antisense therapies which is not susceptible to nuclease degradation in vivo and has a high binding affinity and specificity for the target mRNAs and which can efficiently regulate expression of specific genes. The novel artificial nucleoside of the present invention has an amide bond introduced into a bridge structure of 2′,4′-BNA/LNA. The oligonucleotide containing the 2′,4′-bridged artificial nucleotide has a binding affinity for a single-stranded RNA comparable to known 2′,4′-BNA/LNA and has an increased nuclease resistance over LNA. Particularly, it is expected to be applied to nucleic acid drugs because of its much stronger binding affinity for single-stranded RNAs than S-oligo's affinity | 08-16-2012 |
20120238736 | DEVICE FOR SHEARING NUCLEIC ACIDS AND PARTICULATES - Disclosed herein is a device for shearing nucleic acids and particulates in a syringe or vial comprising an ultrasonic transducer attached to a solid cylindrical horn comprising a tip shaped to engage the profile of the tip of a syringe or vial. The horn tuned for maximum amplitude vibration at its tip. | 09-20-2012 |
20120238737 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS - Aspects of the invention include 2′ protected nucleoside monomers that are protected at the 2′ site with thiocarbon protecting groups. Thiocarbon protecting groups of interest include thiocarbonate, thionocarbonate, dithiocarbonate groups, as well as thionocarbamate protecting groups. Aspects of the invention further include nucleic acids that include the protecting groups of the invention, as well as methods of synthesizing nucleic acids using the protecting groups of the invention. | 09-20-2012 |
20120238738 | Oligonucleotide Adapters: Compositions and Methods of Use - Compositions are provided that include a synthetic oligonucleotide characterized by a double-stranded region, a single-stranded region, a forward primer site, a reverse primer site and one or more cleavage sites therebetween. Methods of use for these compositions include adaptors for the amplification of DNA fragments. | 09-20-2012 |
20120245337 | NUCLEIC ACID PURIFICATION METHOD - The present intimation relates to a method for purifying nucleic acids from a sample containing nucleic acids, the method comprising at least the following steps: a. bringing the sample containing nucleic acids into contact with a nucleic acid binding phase comprising protonatable groups, wherein the protonatable groups have a pKa value of 9 to 12; b. binding the nucleic acids to the nucleic acid phase at a pH (binding pH) that is at least one pH unit less than the pKa value of at least one of the protonatable groups; c. eluting the nucleic acids at a pH greater than the binding pH but at least one pH unit less than the pKa value of at least one of the protonatable groups. Also disclosed are corresponding kits and nucleic acid binding phases that can be used for purifying nucleic acids. | 09-27-2012 |
20120253026 | Expanding the Eukaryotic Genetic Code - This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided. | 10-04-2012 |
20120259104 | SELF-AMPLIFYING FOLDED OLIGONUCLEOTIDE STRUCTURE - The present invention relates to a self-amplifying folded oligonucleotide structure for sensitive oligonucleotide sensing without polymerase chain reaction (PCR). A self-amplifying folded oligonucleotide structure comprise a target sensing sequence having stem loop structure, a signaling molecule and signal modifying molecule labeled two stems wherein the two stems include oligonucleotide sequence that is complementary to a target sensing sequence of another self-amplifying folded oligonucleotide structure. | 10-11-2012 |
20120264926 | Orthogonal Q-Ribosomes - The invention relates to 16S rRNA comprising a mutation at A1196, and to 16S rRNA further comprising a mutation at C1195 and/or A1197, and to 16S rRNA which comprises (i) C1195A and A1196G; or (ii) C1195T, A1196G and A1197G; or (iii) A1196G and A1197G. The invention also relates to ribosomes comprising such 16S rRNAs and to use of same. | 10-18-2012 |
20120283423 | APPARATUS, SYSTEM AND METHOD FOR PURIFYING NUCLEIC ACIDS - Methods and devices for isolating nucleic acids from a mixture containing such nucleic acids and extraneous matter are provided. In one embodiment, the method of the invention comprises passing the mixture through a glass frit under conditions effective to separate the nucleic acids from the extraneous matter. In a more specific embodiment, the glass frit is a sintered glass frit. | 11-08-2012 |
20120316325 | DNA APTAMER SPECIFICALLY BINDING TO pLDH (PLASMODIUM LACTATE DEHYDROGENASE) - Disclosed herein are a DNA aptamer specifically binding to pLDH ( | 12-13-2012 |
20120316326 | DNA APTAMER SPECIFICALLY BINDING TO HUMAN CARDIAC TROPONIN I - Disclosed are a DNA aptamer specifically binding to human cardiac troponin I, and a composition and a diagnostic kit for the diagnosis of acute cardiovascular diseases, comprising the same. Being superior in specificity and stability to antibodies which are conventionally used to diagnose acute cardiovascular diseases, the DNA aptamers specifically binding to human cardiac troponin I can be developed into biosensors which determine human cardiac troponin I levels with high sensitivity and accuracy, greatly contributing to the diagnosis in an early stage of acute cardiovascular diseases. It is expected to lots of help for increase of diagnostic accuracy. | 12-13-2012 |
20120322991 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types - The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes. | 12-20-2012 |
20130012693 | Aptamers to Beta-NGF and Their Use in Treating Beta-NGF Mediated Diseases and Disorders - The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to β-NGF; pharmaceutical compositions comprising such β-NGF aptamers; and methods of making and using the same. | 01-10-2013 |
20130023655 | METHOD FOR PRECIPITATING ANIONIC SURFACTANT IONS IN THE PRESENCE OF NUCLEIC ACIDS - The present invention relates to a method for selectively precipitating anionic surfactant ions from a liquid sample comprising anionic surfactant ions and nucleic acids, as well as to a kit for the isolation and purification of nucleic acids. | 01-24-2013 |
20130030163 | METHOD FOR ISOLATING AND PURIFYING NUCLEIC ACIDS - The present invention relates to a method for isolating and purifying nucleic acids, preferably comprising genomic DNA, from biological samples comprising the steps of lysing the sample using a lysis buffer comprising a source of anionic surfactant ions, optionally disintegrating the RNA present in the lysate, precipitating the surfactant ions from the lysate, and separating the nucleic acids from the precipitate and further contaminants by size-exclusion chromatography. The invention furthermore relates to a lysis buffer, a method of lysing cells and a kit for the isolation and purification of nucleic acids. | 01-31-2013 |
20130046083 | OLIGONUCLEOTIDE LIGATION - Oligonucleotide chemistry is central to the advancement of core technologies such as DNA sequencing, forensic and genetic analysis and has impacted greatly on the discipline of molecular biology. Oligonucleotides and their analogues are essential tools in these areas. They are often produced by automated solid-phase phosphoramidite synthesis but it is difficult to synthesize long DNA and RNA sequences by this method. Methods are proposed for ligating oligonucleotides together, in particular the use of an azide-alkyne coupling reaction to ligate the backbones of oligonucleotides together to form longer oligonucleotides than can be synthesized using current phosphoramidite synthesis methods. | 02-21-2013 |
20130046084 | OLIGONUCLEOTIDE LIGATION - Oligonucleotide chemistry is central to the advancement of core technologies such as DNA sequencing, forensic and genetic analysis and has impacted greatly on the discipline of molecular biology. Oligonucleotides and their analogues are essential tools in these areas. They are often produced by automated solid-phase phosphoramidite synthesis but it is difficult to synthesize long DNA and RNA sequences by this method. Methods are proposed for ligating oligonucleotides together, in particular the use of an azide-alkyne coupling reaction to ligate the backbones of oligonucleotides together to form longer oligonucleotides that can be synthesized using current phosphoramidite synthesis methods. | 02-21-2013 |
20130053552 | FRAGMENT SWITCH: A REVERSE GENETIC APPROACH - The present invention relates to the field of reverse genetics. More particularly, the present invention relates to a novel reverse genetic approach termed “fragment switch” which is used to generate an allelic series in genes of interest which are useful for functional analysis. | 02-28-2013 |
20130072669 | Covalently Functionalized Carbon Nanostructures and Methods for Their Separation - The present invention is directed to carbon nanostructures, e.g., carbon nanotubes, methods of covalently functionalizing carbon nanostructures, and methods of separating and isolating covalently functionalized carbon. In some embodiments, carbon nanotubes are reacted with alkylating agents to provide water soluble covalently functionalized carbon nanotubes. In other embodiments, carbon nanotubes are reacted with a thermally-responsive agent and exposed to light in order to separate carbon nanotubes of a specific chirality from a mixture of carbon nanotubes. | 03-21-2013 |
20130072670 | RNA SYNTHESIS-PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3'-END - The present invention relates to novel phosphoramidites, A-n-bz, C-n-bz, C-n-ac, G-n-ac and U are produced with an HPLC purity of greater than 98% and | 03-21-2013 |
20130109848 | Multidimensional Supramolecular Structures Essentially Made of Assembled I-Motif Tetramers | 05-02-2013 |
20130116419 | POST-SYNTHETIC CHEMICAL MODIFICATION OF RNA AT THE 2'-POSITION OF THE RIBOSE RING VIA "CLICK" CHEMISTRY - This invention relates to the post-synthetic chemical modification of RNA at the 2′-position on the ribose ring via a copper catalyzed Huisgen cycloaddition (“click” chemistry: Kolb, Sharpless Drug Discovery Today 2003, 8, 1128). The invention 1) avoids complex, tedious multi-step syntheses of each desired modified ribonucleoside; 2) allows diverse chemical modifications using high-fidelity chemistry that is completely orthogonal to commonly used alkylamino, carboxylate and disulfide linker reactivities; 3) allows introduction of functional groups that are incompatible with modern automated solid-phase synthesis of RNA and subsequent cleavage-deprotection steps; 4) allows introduction of functional groups useful as targeting ligands; and 5) enables high-throughput structure-activity relationship studies on chemically modified RNA in 96-well format. | 05-09-2013 |
20130116420 | 5' MODIFIED NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM - The present invention provides 5′ modified nucleosides and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides having at least one 5′-substituent and an optional 2′ substituent, oligomeric compounds comprising at least one of these modified nucleosides and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. | 05-09-2013 |
20130123478 | METHODS OF PREPARING TARGETED APTAMER PRODRUGS - The present invention provides methods of preparing an oligonucleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells, the method comprising (1) selecting a targeted aptamer, internalizing nucleic acid or tumor-homing nucleic acid via iterative rounds of selection, and (i) hybridizing it to an oligonucleotide, (ii) replacing one or more nucleotide with a nucleoside or nucleoside analog, or (iii) synthesizing the it with one or more nucleoside or nucleoside analogs; or (2) preparing a naive combinatorial aptamer, internalizing nucleic acid or tumor-homing nucleic acid prodrug library, and running iterative rounds of selection for the cells. The present invention also provides the agent, the pharmaceutical composition, and methods of treating or preventing cancer and/or viral infection, the method comprising administration of the oligonucleotide, nucleoside or nucleoside analog for selective introduction into a subject's cells. | 05-16-2013 |
20130123479 | Soluble TNF Receptors and Their Use in Treatment of Disease - The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist. | 05-16-2013 |
20130123480 | Multicomponent Nucleic Acid Enzymes And Methods For Their Use - The present invention relates to Multicomponent Nucleic Acid Enzymes (MNAzymes) and methods for their use. MNAzymes comprise two or more oligonucleotide components which self-assemble in the presence of one or more MNAzyme assembly facilitator molecules to form a catalytically active structure. Compositions for making MNAzymes, and collections of MNAzymes are provided. Also provided are methods for using MNAzymes for the detection, identification and/or quantification of one or more targets. The methods can be practiced in solution-based assays or in assays where one or more reaction components are attached to a support structure. The methods allow for multiplexing the MNAzyme detection to detect multiple targets in a single reaction. Also provided are kits for making the compositions, and for practicing the methods provided herein. | 05-16-2013 |
20130123481 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF - The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them. | 05-16-2013 |
20130123482 | NUCLEOTIDE AND/OR OLIGONUCLEOTIDE AND PREPARATION PROCESS THEREOF - Nucleotide and/or oligonucleotide represented by formula (1) and the liquid phase synthesis process thereof. The present invention provides a liquid phase synthesis process for preparing a nucleotide and/or an oligonucleotide, comprising a process for combining the nucleotide and/or oligonucleotide protective groups, in which, under the condition that the 2′-hydroxyl group is protected by a group with a sterically hindered silane structure, the 3′ phosphate group(s) of the nucleotide and/or oligonucleotide is/are directly protected by (a)β-cyanoethyl group(s), and after the β-cyanoethyl group(s) is/are removed, the resulting product can directly participate in the next cycle of synthesis, wherein the synthesis reaction is carried out in a reaction flask or reaction kettle, without being limited by a solid carrier or synthesizer, so that the large scale preparation of oligonucleotides can be achieved. | 05-16-2013 |
20130144047 | FORENSIC IDENTIFICATION - The invention provides allelic ladder mixtures and individual alleles suitable for use in such mixtures. The allelic ladder mixtures give improved identification and distinguishing capabilities, particularly suitable in forensic investigations. | 06-06-2013 |
20130158243 | PROCESS FOR CONJUGATION OF NHS ESTERS WITH OLIGONUCLEOTIDES - The present invention provides processes for the conjugation of NHS esters to amino-modified oligonucleotides. The processes provide the amino-modified oligonucleotide on a solid support such that conjugation can be carried out under conditions that can accommodate a wide variety of NHS esters and oligonucleotides. | 06-20-2013 |
20130158244 | Modular Functional Peptides for the Intracellular Delivery of Nanoparticles - Described are nucleic acids encoding a polypeptide for delivery of a nanoparticle to the cytosol, the peptide comprising: (a) a nanoparticle association domain, (b) a spacer domain, (c) an uptake domain, and (d) a vesicle escape domain, wherein the domains (a) through (d) appear in the same order as listed above, and wherein the peptide, upon addition of a non-hydrolyzable lipophilic moiety to the vesicle escape domain and binding to a nanoparticle, is effective to induce uptake of a nanoparticle by a cell and delivery of the nanoparticle to the cytosol of the cell. Also described are methods of delivery of a nanoparticle to the cytosol of a cell, the method comprising providing to a cell a nanoparticle attached to such a peptide. Exemplary nanoparticles include quantum dots. | 06-20-2013 |
20130178610 | OLIGONUCLEOTIDE SPECIFIC UPTAKE OF NANOCONJUGATES - The present invention concerns nanoparticles functionalized with an oligonucleotide and a domain for a variety of uses, including but not limited to gene regulation. More specifically, the disclosure provides a nanoparticle that is taken up by a cell at an efficiency different than a nanoparticle functionalized with the same oligonucleotide but does not contain a domain. | 07-11-2013 |
20130178611 | Novel Nucleic Acid Having Adjuvanticity and Use Thereof - The disclosed nucleic acid at least containing a single-stranded DNA to be delivered to endosomes of dendritic cells and a double-stranded RNA capable of activating TLR3 can be delivered to endosomal TLR3 and has a strong adjuvanticity with few side effects, and therefore is useful as an active ingredient of immunostimulants, vaccine adjuvants, cancer therapeutic agents and the like. | 07-11-2013 |
20130178612 | CHIRAL AUXILIARIES - Chiral auxiliaries useful for efficiently producing a phosphorus atom-modified nucleic acid derivative with high stereoregularity, and compounds represented by the following the general formula (I) or the general formula (XI) for introducing the chiral auxiliaries. | 07-11-2013 |
20130184446 | MICROORGANISM NUCLEIC ACID PURIFICATION FROM HOST SAMPLES - The present disclosure provides systems, devices, and methods for purifying microorganism nucleic acid from a host sample, such as a whole blood sample from a human. In certain embodiments, devices and systems with multiple filters are employed and provide for the selective removal of blood cells and host nucleic acids from a sample in order to enrich for microorganism nucleic acid. | 07-18-2013 |
20130184447 | METAL COORDINATED COMPOSITIONS - A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof. | 07-18-2013 |
20130197206 | METHOD FOR ACQUISITION OF SMALL RNA - The purpose of the present invention is to provide a method which is applicable to high throughput and by which small RNA can be obtained simply and efficiently. The present invention relates to a method for acquisition of small RNA, comprising contacting a carrier, in which a substance having affinity to small RNA-binding protein is immobilized on its surface, with a complex of the small RNA-binding protein and a small RNA (protein-RNA complex) to bind the protein-RNA complex to the aforementioned carrier, and releasing the small RNA by heating the carrier bound with the aforementioned protein-RNA complex at 70° C. to 100° C. in water or buffer solution of pH 3.0 to pH 8.0 | 08-01-2013 |
20130231470 | DEFIBROTIDE FOR USE IN PROPHYLAXIS AND/OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) - Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus Host Disease of the invention (GVHD) can be acute aGVHD and/or chronic cGVHD, preferably acute. | 09-05-2013 |
20130237696 | VASCULAR THERAPEUTICS - The present invention provides a method of preventing or reducing restenosis, neointima formation, graft failure, atherosclerosis, angiogenesis and/or solid tumour growth in a subject. The method comprises administering to the subject a prophylactically effective dose of a nucleic acid which decreases the level of c-Jun mRNA, c-Jun mRNA translation or nuclear accumulation or activity of c-Jun. It is preferred that the nucleic acid is a DNAzymc that targets c-Jun mRNA. | 09-12-2013 |
20130237697 | BUILDING BLOCKS AND METHODS FOR THE SYNTHESIS OF 5-HYDROXYMETHYLCYTOSINE-CONTAINING NUCLEIC ACIDS - The present invention relates to building blocks and methods for the efficient synthesis of 5-hydroxymethylcytosine-containing nucleic acids such as DNA or RNA. | 09-12-2013 |
20130245243 | FUNCTIONAL LIGANDS TO TARGET MOLECULES - The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules. The present invention further relates to methods for generating, for example, functional biomolecules, particularly to functional nucleic acids, that bind with functional activity to another biomolecule, such as a receptor molecule. More than one or multiple targets as used herein may generally include different types of targets, and/or may also include a multitude of a singular type of targets at different conditions, such as, for example, temperature, pH, chemical environment, and/or any other appropriate conditions. | 09-19-2013 |
20130253178 | 2'-O-MODIFIED RNA | 09-26-2013 |
20130253179 | Functionalization Processes and Reactants Used in Such Processes Using an Isatoic Anhydride or a Derivative Thereof, Biological Molecules Thus Treated and Kits - The present invention relates to a process of functionalising at least one ribonucleic acid (RNA) molecule which comprises the following steps:
| 09-26-2013 |
20130261292 | DNA-Guided Nanoparticle Assemblies - In some embodiments, DNA-capped nanoparticles are used to define a degree of crystalline order in assemblies thereof. In some embodiments, thermodynamically reversible and stable body-centered cubic (bcc) structures, with particles occupying <˜10% of the unit cell, are formed. Designs and pathways amenable to the crystallization of particle assemblies are identified. In some embodiments, a plasmonic crystal is provided. In some aspects, a method for controlling the properties of particle assemblages is provided. In some embodiments a catalyst is formed from nanoparticles linked by nucleic acid sequences and forming an open crystal structure with catalytically active agents attached to the crystal on its surface or in interstices. | 10-03-2013 |
20130267695 | Nuclions and Ribocapsids - The invention relates to an isolated nuclion having (i) a core nucleic acid, and (ii) one or more ribocapsids each including a polymer of two or more ribocapsid subunits, wherein said ribocapsid subunits include nucleic acid. The invention also relates to a method for manufacturing an isolated nuclion. | 10-10-2013 |
20130281682 | SYNTHESIS OF PHOSPHITYLATED COMPOUNDS USING A QUATERNARY HETEROCYCLIC ACTIVATOR - A method for preparing a phosphitylated compound comprising the step of:—reacting a hydroxyl containing compound with a phosphitylating agent in the presence of an activator having the formula (I) wherein R=alkyl, cycloalkyl, aryl, aralkyl, heteroalkyl, heteroaryl R | 10-24-2013 |
20130289257 | FORMULATIONS FOR NUCLEIC ACID STABILIZATION ON SOLID SUBSTRATES - The present disclosure generally relates to dry solid matrices for the extraction, stabilization, and storage of nucleic acids, particularly RNA, in a dry format under ambient conditions for a prolonged period of time. Methods for collecting and recovering the nucleic acids stored in the dry solid matrix are also described. | 10-31-2013 |
20130289258 | METHODS OF INDUCING INSULIN PRODUCTION - The present invention provides a method of inducing insulin production in a cell by up-regulating a target gene involved in insulin production in said cell using an saRNA (short activating ribonucleic acid) which specifically down-regulates a target antisense RNA transcript present in said cell, wherein (i) said target RNA transcript is complementary to a sequence located on the coding strand of the target gene between 1000 nucleotides upstream and 1000 nucleotides downstream of the transcription start site of the target gene; and (ii) said sRNA is a single or double stranded RNA molecule up to 30 nucleotides in length comprising a sequence of at least 13 nucleotides which has at least 95% complementarity to a region of the target transcript. Also provided are certain saRNA molecules and uses thereof, particular medical uses, and induced cells and uses thereof. | 10-31-2013 |
20130289259 | APTAMER LABELLED WITH F-19 NUCLEUS FOR TARGETED MOLECULAR IMAGING BY MRI - Magnetic Resonance Imaging based on | 10-31-2013 |
20130310548 | NUCLEIC ACID CONSTRUCT AND METHOD OF PREPARING NANOPARTICLE USING THE SAME - A nucleic acid construct, a method of preparing a nanoparticle by using the nucleic acid construct, and a nanoparticle and nanoparticle complex prepared using the method. Various types of metal nanoparticles may be efficiently prepared using the template for preparing a nanoparticle and the nanoparticle prepared using the template. | 11-21-2013 |
20140018526 | DNA sequence in plant caragana jubata with freeze tolerance - An isolated DNA sequence set forth in SEQ ID NO: 33, which is differentially expressed in apical buds of plant | 01-16-2014 |
20140024818 | ALIGNMENT OF NANOMATERIALS AND MICROMATERIALS - The present invention provides a method for preparing a nanoassembly that includes the step of reacting the assembly template with at least one nanomaterial to form the nanoassembly using a bifunctional linker. | 01-23-2014 |
20140024819 | PURIFICATION OF TRIPHOSPHORYLATED OLIGONUCLEOTIDES USING CAPTURE TAGS - The present invention relates to a method of preparing triphosphate-modified oligonucleotides using a capture tag. The method allows the synthesis and purification of triphosphate-modified oligonucleotides in high yield and purity suitable for pharmaceutical applications. | 01-23-2014 |
20140031537 | OLIGONUCLEOTIDES FOR MODULATION OF TARGET RNA ACTIVITY - The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a micro RNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics. | 01-30-2014 |
20140039172 | DEVICES AND SYSTEMS FOR ISOLATING BIOMOLECULES AND ASSOCIATED METHODS THEREOF - A device, a system, and a method for isolating biomolecules from biological materials are provided. The device comprises a quartz-based solid phase extraction matrix comprising one or more reagents impregnated therein; and an electroosmotic pump (EOP) operationally coupled to the quartz-based solid phase extraction matrix to elute the nucleic acids, wherein the EOP comprises a plurality of electroosmotic membranes comprising one or more positive electroosmotic membranes and one or more negative electroosmotic membranes disposed alternatively and a plurality of electrodes comprising one or more cathodes and one or more anodes, wherein at least one cathode is disposed on one side of one of the membranes and at least one anode is disposed on another side of that membrane and at least one cathode or anode is disposed between a positive electroosmotic membrane and a negative electroosmotic membrane. | 02-06-2014 |
20140039173 | GENERATION AND REPRODUCTION OF DNA SEQUENCES AND ANALYSIS OF POLYMORPHISMS AND MUTATIONS BY USING ERROR-CORRECTING CODES - The present invention relates to a method that uses error-coding codes for validating polymorphisms and mutations/alterations in a DNA sequence which encodes a polypeptide sequence. The present invention also relates to a digital communication system for carrying out the method, employing a model for the biological coding system which resembles the most efficient digital communication. The method and digital communication system may be useful for the predictive analysis of diseases originated by mutations or polymorphisms in genes. | 02-06-2014 |
20140066610 | SPATIAL SEQUESTRATION OF DYNAMIC NUCLEIC ACID CIRCUITS - The invention provides systems and methods for spatial sequestration of elements in nucleic acid circuits. | 03-06-2014 |
20140081011 | Aptamers to 4-1BB and Their Use in Treating Diseases and Disorders - The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to 4-1BB; pharmaceutical compositions comprising such 4-1BB aptamers; and methods of making and using the same. | 03-20-2014 |
20140121363 | Bioreactive Agents - This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. The invention also relates to targets isolated with conjugates which may be useful as pharmaceutical agents or compositions that can be administered to humans and other mammals. The invention further relates to kits comprised of agents and conjugates that can be used for the detection of diseases, disorders and individual substances in a complex background of substances. | 05-01-2014 |
20140128587 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI - The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures. | 05-08-2014 |
20140128588 | COMPOSITIONS OF MATTER THAT REDUCE PAIN, SHOCK, AND INFLAMMATION BY BLOCKING LINOLEIC ACID METABOLITES AND USES THEREOF - A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs. | 05-08-2014 |
20140128589 | METHOD FOR EVALUATING REDOX ACTIVITY OF NUCLEIC ACID MOLECULE AND NUCLEIC ACID MOLECULE HAVING REDOX ACTIVITY - The present invention provides a novel technique by which the redox activity of a nucleic acid molecule can be evaluated. An evaluation method of the present invention includes: a detection step of electrochemically detecting a redox reaction to a substrate, the redox reaction being catalyzed by a nucleic acid molecule to be evaluated, using a device that electrochemically detects a redox reaction; and an evaluation step of evaluating redox activity of the nucleic acid molecule from a result of the detection of the redox reaction. As the device, a device in which a base provided with a detection portion is included, the detection portion. | 05-08-2014 |
20140135487 | IMMUNOSTIMULATORY G, U-CONTAINING OLIGORIBONUCLEOTIDES - Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening candidate immunostimulatory compounds are also provided. | 05-15-2014 |
20140142288 | THERAPEUTIC COMPOUNDS - The present invention is directed to RNA interference (RNAi) molecules targeted against a Huntington's disease nucleic acid sequence, and methods of using these RNAi molecules to treat Huntington's disease. | 05-22-2014 |
20140148589 | RAPID ASSEMBLY OF MULTIPLE ARBITRARY LENGTH DNA FRAGMENTS - Aspects herein relate to composition, and related methods, for isolating and assembling DNA molecules without intermediate cloning steps. | 05-29-2014 |
20140163213 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity - The invention relates to oligonucleotides including at least one lipophilic substituted nucleotide analog and a pyrimidine-purine dinucleotide. The invention also relates to pharmaceutical compositions and methods of use thereof. | 06-12-2014 |
20140171632 | APPARATUS AND METHOD FOR SEPARATING FIBROUS MATERIAL - An apparatus for separating fibrous materials includes: an introduction unit through which fibrous materials capable of performing Brownian motion are introduced; a moving path providing section prepared in a state in which at least one field causing movement of the fibrous materials in a predetermined direction is applied thereto, and providing a moving path for the fibrous materials; at least three capture zone-providing segments provided to the moving path providing section so as to at least temporarily capture the fibrous materials; and an collecting unit collecting the fibrous materials having passed through the moving path providing section. The apparatus and method have improved safety and improved purity of separated fibrous materials, enables separation of large amounts of fibrous materials through a simple separation process, and the apparatus and method have other various advantages inferred from the spirit of the invention. Therefore, the apparatus and method may significantly increase yield. | 06-19-2014 |
20140171633 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton - Provided is a novel nucleic acid molecule that can be produced easily and efficiently and can inhibit the expression of a gene. The nucleic acid molecule is a single-stranded nucleic acid molecule including an expression inhibitory sequence that inhibits expression of a target gene. The single-stranded nucleic acid molecule includes: a region (X); a linker region (Lx); and a region (Xc). The linker region (Lx) is linked between the regions (Xc) and (Xc). The region (Xc) is complementary to the region (X). At least one of the regions (X) and (Xc) includes the expression inhibitory sequence. The linker region (Lx) has a non-nucleotide structure including at least one of a pyrrolidine skeleton and a piperidine skeleton. According to this single-stranded nucleic acid molecule, it is possible to inhibit the expression of the target gene. | 06-19-2014 |
20140194607 | ISOLATION OF NUCLEIC ACIDS - Provided herein is technology relating to isolating nucleic acids. In particular, the technology relates to methods and kits for extracting nucleic acids from problematic samples such as stool. | 07-10-2014 |
20140194608 | ISOLATION OF NUCLEIC ACIDS - Provided herein is technology relating to isolating nucleic acids. In particular, the technology relates to methods and kits for extracting nucleic acids from problematic samples such as stool. | 07-10-2014 |
20140194609 | ISOLATION OF NUCLEIC ACIDS - Provided herein is technology relating to isolating nucleic acids. In particular, the technology relates to methods and kits for extracting nucleic acids from problematic samples such as stool. | 07-10-2014 |
20140194610 | METHODS FOR THE SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS - Described herein are methods for the synthesis of derivatives of thiosulfonate reagents. Said reagents have utility for the synthesis of phosphorothiotriesters from H-phosphonates in a stereospecific fashion. | 07-10-2014 |
20140200337 | Methods and Compositions of DNA Ligands for Arthropod-Borne Pathogen Detection and Prophylaxis or Therapy - Specific DNA ligand sequences for binding various arthropod-borne pathogens including arboviruses, | 07-17-2014 |
20140213778 | COMPOSITIONS AND METHODS RELATING TO NUCLEIC ACID NANO- AND MICRO-TECHNOLOGY - The invention provides nucleic acid structures of controlled size and shape, comprised of a plurality of oligonucleotides, and methods for their synthesis. The structures are formed, at least in part, by the self-assembly of single stranded oligonucleotides. The location of each oligonucleotide in the resultant structure is known. Accordingly, the structures may be modified with specificity. | 07-31-2014 |
20140235841 | DOUBLE-STRANDED RIBONUCLEIC ACIDS WITH RUGGED PHYSICO-CHEMICAL STRUCTURE AND HIGHLY SPECIFIC BIOLOGIC ACTIVITY - The invention relates to our discovery of a novel double-stranded ribonucleic acid (dsRNA) having specific biological activities, which includes acting as a selective agonist for activation of the Toll-like receptor 3. Its “rugged” molecular structure as measured by physico-chemical techniques is resistant to molecular unfolding (i.e., denaturation). This structure appears to be responsible for increased efficacy of dsRNA in therapeutic applications and improved biological activity (e.g., used as an immunoregulatory agent). Medicaments, processes for their manufacture, and methods for their use are provided herein. | 08-21-2014 |
20140235842 | CONVENIENT AND EFFICIENT PURIFICATION METHOD FOR CHEMICALLY LABELED NUCLEIC ACIDS - The present invention relates to a method for purifying chemically labeled nucleic acids. More particularly, the present invention relates to a convenient and efficient method for purifying labeled nucleic acids in a fast manner with high efficiency from a mixture of unreacted hydrophobic probes, unreacted nucleic acids and labeled nucleic acids. | 08-21-2014 |
20140256926 | Ionic Tags for Synthesis of Oligoribonucleotides - The invention relates to the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. In another aspect, the invention relates to compounds of formula (II) processes for making these compounds, and the use thereof in the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. The invention also relates to methods of synthesis of oligomers, including but not limited to oligopeptides, oligosaccharides and oligonucleotides, particularly oligoribonucleotides and also oligodeoxyribonucleotides, in solution systems, and ionic tag linkers for use in methods provided herein. | 09-11-2014 |
20140256927 | INCREASING THE LIPID CONTENT IN MICROALGAE BY GENETICALLY MANIPULATING A TRIACYLGLYCEROL (TAG) LIPASE - The present invention relates to a method of increasing the lipid content in an organism, in particular a micro algae by modulating the activity of a triacylglycerol (TAG) lipase. The invention also concerns organisms produced by this method, or microalgae, with increased lipid content, as well as their use in industry and medicine; in particular to obtain omega-3 unsaturated fatty acids. The invention relates furthermore to a nucleic acid from | 09-11-2014 |
20140275509 | MULTIFUNCTIONALIZED MATERIALS - The present invention describes a method for producing multifunctional materials comprising the steps of: a) chemically activating functional groups present in a micro- or nanoparticulate base material; b) performing a nucleophilic substitution reaction between at least one terminal amino, carboxyl or thiol group of a PNA or DNA type A chain and at least one activated functional group of the base material produced in step (a); c) conjugating to a biomolecule by means of chemically activating functional groups of a PNA/DNA type B chain, which is complementary to the PNA/DNA type A chain; and d) hybridizing the PNA/DNA type A chains which are bound to the base material according to step b) and the PNA/DNA type B chains having biomolecules bound thereto according to step c) by means of PNA-PNA or PNA-DNA molecular recognition. | 09-18-2014 |
20140296500 | Methods and Compositions of Nucleic Acid Ligands for Detection of Clinical Analytes Related to Human Health - Specific DNA sequences for binding various clinically relevant analytes from the human body are described. Each of these sequences or their linear, two- and three-dimensional linked sequences can function in varying assay and sensor formats with varying degrees of success. Linkage of the whole or partial DNA sequences (putative binding sites) can be used to enhance specificity and affinity towards complex targets, thereby improving assay selectivity and sensitivity in many instances. In addition, a FRET-based quantitative method is described for normalizing analyte data by assessing urine creatinine and urea levels. Finally, a method is described for removing creatinine or urea by size-exclusion chromatography prior to a FRET-based aptamer assay to avoid the denaturing effects of these compounds. | 10-02-2014 |
20140296501 | Aptamers and Diagnostic Methods for Detecting the EGF Receptor - The present invention provides aptamers that specifically bind to the EGF receptor in a sample, and diagnostic and analytical methods using those aptamers. | 10-02-2014 |
20140316121 | METHODS AND COMPOUNDS USEFUL IN CONDITIONS RELATED TO REPEAT EXPANSION - Described are compounds and methods useful for the treatment and investigation of diseases and disorders associated with expanded repeat-containing RNA molecules. | 10-23-2014 |
20140330002 | Specificity, Flexibility and Valence of DNA Bonds for Guided Emulsion Architecture - A method of forming an end product by self-assembly of a first component having a patch of a linker component, such as DNA strands, cadherins, adhesive proteins and nanoparticle linkers. Such emulsions can be used to process personal care products, skin cremes, foods and animal feedstocks. | 11-06-2014 |
20140343264 | NEUTRAL NUCLEIC ACID LIGANDS - The invention generally relates to isolated nucleic acid ligands that are neutral under physiological conditions. | 11-20-2014 |
20140343265 | METHODS FOR MANIPULATING BIOMOLECULES - In some embodiments, the present teachings provide compositions, systems, methods and kits for generating a population of nucleic acid fragments. In some embodiments, nucleic acids can be fragmented enzymatically. For example, methods for generating a population of nucleic acid fragments can include a nucleic acid nicking reaction. In one embodiment, the methods can include a nick translation reaction. A nicking reaction can introduce nicks at random positions on either strand of a double-stranded nucleic acid. A nick translation reaction can move the position of nicks to a new position so that the new positions of two of the nicks are aligned to create a double-stranded break. In some embodiments, methods for generating a population of nucleic acid fragments can include joining at least one end of a fragmented nucleic acid to one or more oligonucleotide adaptors. | 11-20-2014 |
20140343266 | ANTISENSE NUCLEIC ACIDS - The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. | 11-20-2014 |
20140357849 | SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE - The present invention relates to compositions and methods for preparing splice variants of TNFalpha receptor (TNFR) in vivo or in vitro, and the resulting TNFR protein variants. Such variants may be prepared by controlling the splicing of pre-mRNA molecules and regulating protein expression with splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 or 8 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 or 8 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has therapeutic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH. | 12-04-2014 |
20140357850 | NUCLEIC ACID ENCODING ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 12-04-2014 |
20140357851 | NUCLEIC ACID ENCODING ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 12-04-2014 |
20140364596 | ARTIFICIAL LIPID-POLYMER-DNA COMPLEX, BIOIMAGING AGENT AND PREPARATION METHOD THEREOF - An artificial lipid-polymer-DNA complex, an in-vivo imaging agent, a pharmaceutical composition and a method of preparing the same are provided. The artificial lipid bilayer includes a polymer matrix including polylactic-co-glycolic acid disposed within a lipid membrane. | 12-11-2014 |
20140378675 | Methods for Detecting and Measuring Specific Nucleic Acid Sequences - The invention provides novel oligonucleotides and methods of using the same for detection or measurement of specific nucleic acid molecules. The invention also features nucleic acid arrays comprising the oligonucleotides of the invention. An oligonucleotide of the invention comprises (1) a reporter-binding sequence capable of hybridizing to a fluorophore-labeled reporter sequence and (2) a hairpin-forming sequence capable of forming a stem-loop. Formation of the stem-loop modifies (e.g., quenching) the fluorescence signals of the reporter sequence when the reporter sequence is hybridized to the oligonucleotide. This can be achieved, for example, by bringing one or more guanine based in the oligonucleotide into close proximity to the fluorophore(s) of the reporter sequence by virtue of the formation of the stem-loop. Disruption of the stem-loop, such as by hybridization of a target sequence to at least part of the hairpin-forming sequence, produces a detectable change in the fluorescence signals. | 12-25-2014 |
20150018538 | METHOD AND DEVICE FOR MARKING ARTICLES - Provided are a method and device for marking an article for security, tracking or authentication. The method includes depositing a solution comprising a nucleic acid marker onto at least a portion of the article. The nucleic acid marker may be activated, for example, by adding a functional group to the nucleic acid marker. The activation of the nucleic acid marker may be performed by exposure to alkaline conditions. The method is well suited for marking fibers and textiles, as well as many other items. | 01-15-2015 |
20150038690 | GELATIN-BASED NANOPARTICLE COMPLEX FOR TUMOR-TARGETED DELIVERY OF siRNA AND METHOD FOR PREPARING THE SAME - Disclosed is a gelatin-based nanoparticle complex for tumor-targeted delivery of siRNA for specific gene silencing in tumor cells. The gelatin-based nanoparticle complex includes: poly-siRNA chains whose ends are modified with thiol groups; and thiolated gelatin bound to the poly-siRNA chains through disulfide crosslinking and charge interactions. The gelatin-based nanoparticle complex is not degraded in the bloodstream and can be efficiently absorbed into tumor cells without cytotoxicity. The delivered siRNA can effectively silence target gene expression. Also disclosed is a method for preparing the gelatin-based nanoparticle complex. | 02-05-2015 |
20150045546 | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX - Isolation or in vitro assembly of the Cas9-crRNA complex of the | 02-12-2015 |
20150080562 | METHODS FOR PREPARING SAMPLES FOR NUCLEIC ACID AMPLIFICATION - The present invention is in the field of sample preparation. In particular, it relates to methods for preparing samples prior to performing nucleic acid amplification. | 03-19-2015 |
20150112050 | ENDOTOXIN ADSORBENT - A means for selectively removing ET under coexistence of a substance showing a negative charge, such as nucleic acid is described. Endotoxin is selectively removed by bringing a polymer obtained by crosslinking cyclodextrin with an isocyanate-based crosslinking agent in contact with a solution containing endotoxin and the substance showing the negative charge such as nucleic acid. | 04-23-2015 |
20150112051 | CONSTRUCTION OF CELL PENETRATING NUCLEIC ACIDS - This invention provides pH-responsive zwitterionic nucleotides and nucleic acids comprising said nucleotides, wherein said zwitterions are constituted from one or more anionic internucleoside linkages and one or more cationic moieties and said zwitterionic nucleotides further comprise either one or more hydrophobic moieties or one or more TEE's with the general structure (I) Hydrophobic element-pH-responsive hydrophilic elements (I). | 04-23-2015 |
20150126722 | OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING NIDOVIRUS INFECTIONS - A method and oligonucleotide compound for inhibiting replication of a nidovirus in virus-infected animal cells are disclosed. The compound (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the infected cells, (iii) contains between 8-25 nucleotide bases, and (iv) has a sequence capable of disrupting base pairing between the transcriptional regulatory sequences in the 5′ leader region of the positive-strand viral genome and negative-strand 3′ subgenomic region. In practicing the method, infected cells are exposed to the compound in an amount effective to inhibit viral replication. | 05-07-2015 |
20150148528 | CHROMATOGRAPHIC PURIFICATION OF POLYNUCLEOTIDES WITH NEGATIVELY CHARGED PARTICLES - A method of purifying a sample that includes a polynucleotide includes the steps of (i) providing a packed chromatographic column having negatively charged porous particles, (ii) equilibrating the column to the conditions to which the polynucleotide in the sample is to elute, (iii) contacting the sample with the packed chromatographic column such that the sample volume applied to the packed chromatographic column is less than or equal to the interparticle space of the negatively charged porous particles within the packed chromatographic column, (iv) eluting the polynucleotide from the packed chromatographic column, where the polynucleotide is in a purer state and in the conditions to which the packed chromatographic column was equilibrated. | 05-28-2015 |
20150297624 | DEFIBROTIDE FOR USE IN PROPHYLAXIS AND/OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) - Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus Host Disease of the invention (GVHD) can be acute aGVHD and/or chronic cGVHD, preferably acute. | 10-22-2015 |
20150307542 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF - The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them. | 10-29-2015 |
20150307884 | DOUBLE-STRANDED RIBONUCLEIC ACID FOR ADJUVANTS - The invention provides a double-stranded ribonucleic acid (dsRNA) having a chain length suitable for simultaneously showing low toxicity and high function in the use of an adjuvant and the like, and resisting variation of chain length even when subjected to a heating and cooling treatment, or a salt thereof; an immune potentiator, adjuvant, pharmaceutical product and the like containing the dsRNA and the like; and a production method of such dsRNA and the like. The invention is characterized in that the weight average chain length of two or more single-stranded ribonucleic acids (ssRNAs) constituting the first chain constituting dsRNA is not more than ½ of the weight average chain length of one ssRNA constituting the second chain. | 10-29-2015 |
20150322425 | RNA APTAMERS AND METHODS FOR IDENTIFYING THE SAME - RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed. | 11-12-2015 |
20150329584 | COMPOSITIONS AND METHODS RELATING TO COMPLEX NUCLEIC ACID NANOSTRUCTURES - The invention provides SST motifs of controlled size and shape, comprised of a plurality of oligonucleotides, and methods for their synthesis. The motifs are formed, at least in part, by the self-assembly of single stranded oligonucleotides into curved, corrugated or twisted structures. The location of each oligonucleotide in the resultant motif is known. Accordingly, the motifs may be modified with specificity. | 11-19-2015 |
20150353932 | FUNCTIONAL LIGANDS TO TARGET MOLECULES - The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules. | 12-10-2015 |
20150353933 | APTAMER AGAINST MIDKINE AND APPLICATIONS THEREOF - The present invention provides an aptamer binding to midkine and capable of forming a potential secondary structure represented by the formula (I): | 12-10-2015 |
20150368287 | NUCLEOSIDE AND NUCLEOTIDE HAVING NITROGEN-CONTAINING HETEROCYCLE STRUCTURE - The present invention provides compounds shown by the formula: | 12-24-2015 |
20150376220 | METHODS FOR PURIFICATION OF MESSENGER RNA - The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution. In some embodiments, a purification process involving membrane filtration suitable for the present invention is tangential flow filtration. | 12-31-2015 |
20160002280 | TRICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM - The present invention provides fluorine substituted tricyclic nucleosides of formula (I) wherein: the substituents are as defined in the claims. The present invention further provides oligomeric compounds prepared therefrom. Incorporation of one or more of the tricyclic nucleosides into an oligomeric compound enhances one or more properties of the oligomeric compound. Such oligomeric compounds can also be included in double stranded compositions. | 01-07-2016 |
20160002705 | QUANTITATIVE ASSESSMENT FOR CAP EFFICIENCY OF MESSENGER RNA - The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro. In some embodiments, methods according to the present invention comprise providing an mRNA sample containing capped and uncapped mRNA, providing a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA, and quantitatively determining the amount of the complex as compared to a control, thereby quantifying mRNA capping efficiency. | 01-07-2016 |
20160024139 | RNA PURIFICATION METHODS - Methods for purifying RNA from a sample, comprising one or more steps of tangential flow filtration, hydroxyapatite chromatography, core bead flow-through chromatography, or any combinations thereof. These techniques are useful individually, but show very high efficiency when used in combination, or when performed in particular orders. The methods can purify RNA in a highly efficient manner without unduly compromising potency or stability, to provide compositions in which RNA is substantially cleared of contaminants. Moreover, they can be performed without the need for organic solvents. | 01-28-2016 |
20160024141 | ION EXCHANGE PURIFICATION OF MRNA - The current landscape for preparative chromatographic RNA purification uses reversed phase HPLC, but this technique presents many issues with process scale up and ion exchange for preparative purification has only been used for short RNAs. The invention provides preparative purification of RNA (e.g., mRNA) using ion (e.g., anion) exchange chromatography that allows for separation of longer RNAs up to 10,000 nucleotides in length via a scalable method. This method avoids problems with current techniques by using low pressure chromatography that is agreeable with existing equipment in cGMP commercial facilities, that uses aqueous-bases solutions as the mobile phase (rather than flammable of greater than 10 mg RNA/mL resin (e.g., using larger pore sorbents, >500 Angstroms, that display greater mRNA binding capacities), and that yields desired RNA salt forms for downstream formulation with no additional manipulation necessary (unlike ion pair reverse phase techniques). | 01-28-2016 |
20160031922 | NUCLEIC ACID PURIFICATION - Methods and composition for nucleic acid isolation are provided. In one embodiment, the invention provides a method for nucleic acid purification from biological samples extracted with phenol-based denaturing solvents, which does not require phase separation or nucleic acid precipitation. Methods according to the invention may also be used for differential isolation of RNA and DNA. | 02-04-2016 |
20160032251 | CHIMERIC PESTIVIRUS WITH INSERTION IN 3' NONTRANSLATED REGION (3' NTR) WITH STABLE REPLICATION AND RNASE RESISTANCE - The construction of a chimeric Pestivirus by the identification of selected regions in the 3′NTR of the viral RNA genome is described where additional RNA sequences can be stably inserted. These sequence insertions in the viral RNA genome were stable in replication and capable of forming infectious, RNase resistant virus particles. This chimeric Pestivirus with a 3′NTR insertion can be utilized as a quality control material in analytical assays for RNA targets, including external, internal controls, quantitative standards in PCR and NAT nucleic acid assays. | 02-04-2016 |
20160032356 | QUANTITATIVE ASSESSMENT FOR CAP EFFICIENCY OF MESSENGER RNA - The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly for mRNA synthesized in vitro. In some embodiments, the methods comprise chromatographic methods of quantifying capping efficiency and methylation status of the caps. | 02-04-2016 |
20160040154 | METHODS FOR PURIFICATION OF MESSENGER RNA - The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of subjecting an impure preparation comprising in vitro synthesized mRNA to a denaturing condition, and purifying the mRNA from the impure preparation from step (a) by tangential flow filtration, wherein the mRNA purified from step (b) is substantially free of prematurely aborted RNA sequences and/or enzyme reagents used in in vitro synthesis. | 02-11-2016 |
20160040164 | SELECTION OF RNA-APTAMERS AS ANTI-MALARIA AGENTS - The present invention relates to an aptamer or an active fragment thereof raised against the semi-conserved duffy binding ligand domain 1α, DBL1α, region of the | 02-11-2016 |
20160046972 | VERSATILE GENETIC ASSEMBLY SYSTEM (VEGAS) TO ASSEMBLE PATHWAYS FOR EXPRESSION - Provided are compositions and methods for use in assembling and expressing a plurality of transcription units using, in one aspect, homologous recombination in yeast. Yeast containing the plurality of transcription units, and isolated transcription units, are also provided. Kits for use in making the yeast and the transcript units are further included. | 02-18-2016 |
20160060630 | METHOD FOR EVALUATING REDOX ACTIVITY OF NUCLEIC ACID MOLECULE AND NUCLEIC ACID MOLECULE HAVING REDOX ACTIVITY - The present invention provides a novel technique by which the redox activity of a nucleic acid molecule can be evaluated. An evaluation method of the present invention includes: a detection step of electrochemically detecting a redox reaction to a substrate, the redox reaction being catalyzed by a nucleic acid molecule to be evaluated, using a device that electrochemically detects a redox reaction; and an evaluation step of evaluating redox activity of the nucleic acid molecule from a result of the detection of the redox reaction. As the device, a device in which a base provided with a detection portion is included, the detection portion includes an electrode system, and the nucleic acid molecule to be evaluated is arranged on the base is used. In the present invention, it is preferred that a plurality of kinds of nucleic acid molecule to be evaluated is arranged on the base, and the plurality of kinds of nucleic acid molecules to be evaluated is evaluated by a single device. | 03-03-2016 |
20160145606 | Nuclease-Resistant DNA Analogues - The present invention provides stable, nuclease-resistant TNA and TNA-DNA oligonucleotides, wherein the oligonucleotides are completely resistant to enzymatic degradation for at least 24-72 hours. Methods of synthesis and use in diagnostic and therapeutic applications are also provided. Specifically, in one embodiment, we describe the chemical and biological stability of TNA and mixed-backbone (mosaic) TNA-DNA oligonucleotides under a variety of conditions and sequence contexts. | 05-26-2016 |
20160168562 | DEVICE HAVING A FILTER LAYER AND METHOD FOR EXTRACTING NUCLEIC ACIDS FROM FORMALIN-FIXED AND PARAFFIN-EMBEDDED SAMPLES | 06-16-2016 |
20160177307 | PDGF and VEGF Aptamers Having Improved Stability and Their Use in Treating PDGF and VEGF Mediated Diseases and Disorders | 06-23-2016 |
20160200759 | HIGHLY EFFICIENT SYNTHESIS OF LONG RNA USING REVERSE DIRECTION APPROACH | 07-14-2016 |
20160376593 | CHEMICALLY MODIFIED POLYNUCLEOTIDES AND METHOD FOR PRODUCING CHEMICALLY MODIFIED POLYNUCLEOTIDES - The present invention relates to chemically-modified polynucleotides of formula (I): 5′-CONS-SEQ.ID.n-CONS-3′ (I) containing one or more modified pyrimidines and at least one inverted nucleotide repeat, and to the method for producing the same. | 12-29-2016 |
20170233738 | FUNCTIONAL LIGANDS TO NERVE AGENT METABOLITES | 08-17-2017 |
20190142882 | MICROBIAL PRODUCTION OF PURE SINGLE STRANDED NUCLEIC ACIDS | 05-16-2019 |
20190143292 | DEVICE FOR DNA SAMPLE FRAGMENTATION | 05-16-2019 |
20190144480 | METHODS FOR PURIFICATION OF MESSENGER RNA | 05-16-2019 |
20190144488 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | 05-16-2019 |
20190144489 | METHODS AND COMPOSITIONS FOR NUCLEOSIDE TRIPHOSPHATE AND RIBONUCLEIC ACID PRODUCTION | 05-16-2019 |
20190144491 | DNA GRIDIRON COMPOSITIONS AND METHODS | 05-16-2019 |
20190144883 | NOVEL MINIMAL UTR SEQUENCES | 05-16-2019 |
20220135608 | METHODS FOR PURIFICATION OF MESSENGER RNA - The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution. In some embodiments, a purification process involving membrane filtration suitable for the present invention is tangential flow filtration. | 05-05-2022 |